<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002750" GROUP_ID="EPILEPSY" ID="940100032811164597" MERGED_FROM="" MODIFIED="2013-02-27 12:18:31 +0000" MODIFIED_BY="Rachael Kelly" REVIEW_NO="0041" REVMAN_SUB_VERSION="5.2.3 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="11.0">
<COVER_SHEET MODIFIED="2013-02-27 12:18:31 +0000" MODIFIED_BY="Rachael Kelly">
<TITLE>Calcium antagonists as an add-on therapy for drug-resistant epilepsy</TITLE>
<CONTACT MODIFIED="2013-02-27 12:18:31 +0000" MODIFIED_BY="Rachael Kelly"><PERSON ID="63198987208766352467120417092041" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Mohammad</FIRST_NAME><LAST_NAME>Hasan</LAST_NAME><EMAIL_1>dr.mohammadhasan@gmail.com</EMAIL_1><EMAIL_2>M.Hasan@liverpool.ac.uk</EMAIL_2><MOBILE_PHONE>+965 99139239</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Molecular and Clinical Pharmacology</DEPARTMENT><ORGANISATION>Institute of Translational Medicine, University of Liverpool</ORGANISATION><ADDRESS_1>Clinical Sciences Centre, University Hospital Aintree</ADDRESS_1><ADDRESS_2>Lower Lane, Fazakerley</ADDRESS_2><CITY>Liverpool</CITY><ZIP>L9 7AL</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2013-02-27 12:18:31 +0000" MODIFIED_BY="Rachael Kelly"><PERSON ID="63198987208766352467120417092041" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Mohammad</FIRST_NAME><LAST_NAME>Hasan</LAST_NAME><EMAIL_1>dr.mohammadhasan@gmail.com</EMAIL_1><EMAIL_2>M.Hasan@liverpool.ac.uk</EMAIL_2><MOBILE_PHONE>+965 99139239</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Molecular and Clinical Pharmacology</DEPARTMENT><ORGANISATION>Institute of Translational Medicine, University of Liverpool</ORGANISATION><ADDRESS_1>Clinical Sciences Centre, University Hospital Aintree</ADDRESS_1><ADDRESS_2>Lower Lane, Fazakerley</ADDRESS_2><CITY>Liverpool</CITY><ZIP>L9 7AL</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="12654466126280759364110830105954" ROLE="AUTHOR"><FIRST_NAME>Jennifer</FIRST_NAME><LAST_NAME>Pulman</LAST_NAME><EMAIL_1>jennifer.pulman@liv.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Molecular and Clinical Pharmacology</DEPARTMENT><ORGANISATION>Institute of Translational Medicine, University of Liverpool</ORGANISATION><ADDRESS_1>Clinical Sciences Centre for Research and Education, Lower Lane</ADDRESS_1><ADDRESS_2>Fazakerley</ADDRESS_2><CITY>Liverpool</CITY><ZIP>L9 7LJ</ZIP><REGION>Merseyside</REGION><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="555BA85182E26AA20187B7968786091D" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Anthony</FIRST_NAME><MIDDLE_INITIALS>G</MIDDLE_INITIALS><LAST_NAME>Marson</LAST_NAME><POSITION>Professor of Neurology</POSITION><EMAIL_1>a.g.marson@liverpool.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Molecular and Clinical Pharmacology</DEPARTMENT><ORGANISATION>Institute of Translational Medicine, University of Liverpool</ORGANISATION><ADDRESS_1>Clinical Sciences Centre for Research and Education, Lower Lane</ADDRESS_1><ADDRESS_2>Fazakerley</ADDRESS_2><CITY>Liverpool</CITY><ZIP>L9 7LJ</ZIP><REGION>Merseyside</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 151 529 5405</PHONE_1><PHONE_2>+44 151 529 5462</PHONE_2><FAX_1>+44 151 529 5465</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2013-02-27 12:12:32 +0000" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="27" MONTH="2" YEAR="2013"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="29" MONTH="1" YEAR="2013"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="29" MONTH="1" YEAR="2015"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2000"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2001"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2001"/>
</DATES>
<WHATS_NEW MODIFIED="2013-02-27 12:11:42 +0000" MODIFIED_BY="Heather Maxwell">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-02-19 14:17:09 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="29" MONTH="1" YEAR="2013"/>
<DESCRIPTION>
<P>Searches updated 29 January 2013; no new trials identified.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2013-02-27 12:11:29 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="22" MONTH="1" YEAR="2013"/>
<DESCRIPTION>
<P>Conclusions remain the same.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2011-06-16 14:07:50 +0100" MODIFIED_BY="Heather Maxwell">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2011-06-16 14:07:50 +0100" MODIFIED_BY="Heather Maxwell">
<DATE DAY="7" MONTH="10" YEAR="2009"/>
<DESCRIPTION>
<P>Searches updated 7 October 2009; no new trials identified.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2012-06-01 13:01:20 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2012-06-01 13:01:20 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2012-06-01 13:01:20 +0100" MODIFIED_BY="[Empty name]">
<NAME>National Institute for Health Research, UK</NAME>
<COUNTRY CODE="NONE">Not specified</COUNTRY>
<DESCRIPTION>
<P>This review presents independent research commissioned by the National Institute for Health Research (NIHR). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-02-19 15:50:58 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2013-02-19 15:39:39 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2013-02-19 14:20:07 +0000" MODIFIED_BY="[Empty name]">Calcium antagonists as an add-on therapy for drug-resistant epilepsy</TITLE>
<SUMMARY_BODY MODIFIED="2013-02-19 14:21:30 +0000" MODIFIED_BY="[Empty name]">
<P>There is no evidence to suggest that calcium antagonists have a useful effect on seizures.</P>
<P>Nearly a third of people with epilepsy become resistant to antiepileptic drugs. Older drugs do not prevent seizures for everyone, and they have adverse effects. A range of new drugs have been tested as 'add-on' treatments to try and improve the results from antiepileptic drugs. The calcium antagonist drugs flunarizine, nifedipine and nimodipine can be used as an add-on treatment. The review of trials found no evidence to show a useful effect of these particular calcium antagonist drugs on seizures. Adverse effects of the calcium antagonists reviewed included dizziness, fatigue and unsteadiness (ataxia), however the percentage of adverse events were no more significant than with placebo.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-02-19 15:39:05 +0000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2013-02-19 14:17:44 +0000" MODIFIED_BY="[Empty name]">
<P>This is an updated version of the original Cochrane review published in <I>The Cochrane Library </I>2001,<I> </I>Issue 4.</P>
<P>Nearly a third of people with epilepsy do not have their seizures controlled with current treatments. Continuous attempts have been made to find new antiepileptic drugs based on increasing knowledge of the cellular and molecular biology involved in the genesis of epilepsy and seizures. Therefore, calcium antagonists that can alter the effects of calcium on brain cells have been investigated for their effect on epileptic seizures.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To evaluate the effects of calcium antagonists when used as an add-on therapy for people with drug-resistant epilepsy.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-02-19 14:18:02 +0000" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Epilepsy Group Specialized Register (29 January 2013), Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> 2012, Issue 12), MEDLINE (1948 to 29 January 2013) and SCOPUS (all years to 29 January 2013).</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2013-02-19 15:39:05 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised placebo-controlled or active-controlled add-on trials of any calcium antagonist in people with drug-resistant epilepsy.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2013-02-19 14:18:14 +0000" MODIFIED_BY="[Empty name]">
<P>Two review authors (MH and JP) independently selected trials for inclusion and extracted data. Outcomes investigated included 50% or greater reduction in seizure frequency, treatment withdrawal, adverse effects, cognition and quality of life. Analyses were by intention to treat.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2013-02-19 14:19:25 +0000" MODIFIED_BY="[Empty name]">
<P>Eleven trials were included with a total of 424 participants, one parallel-group and seven cross-over trials of flunarizine, two cross-over trials of nimodipine and one cross-over trial of nifedipine.</P>
<P>For flunarizine, the risk ratio (RR) with 95% confidence interval (CI) for a 50% or greater reduction in seizure frequency in a single parallel trial was 1.53 (95% CI 0.59 to 3.96) indicating a non-significant advantage of flunarizine. We were unable to acquire data for this outcome from the other seven cross-over trials. The overall RR for treatment withdrawal of flunarizine was 7.11 (95% CI 1.73 to 29.30) indicating individuals were significantly more likely to have flunarizine withdrawn than placebo. No adverse effects were associated statistically with flunarizine.</P>
<P>For nifedipine, we were unable to acquire the data we required for our specified outcomes.</P>
<P>For nimodipine, we had data only from the first treatment period from one of the two cross-over trials (17 participants). The RR for a 50% or greater reduction in seizure frequency was 7.78 (99% CI 0.46 to 130.88) and for treatment withdrawal the RR was 2.25 (99% CI 0.25 to 20.38).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-02-19 14:19:55 +0000" MODIFIED_BY="[Empty name]">
<P>Flunarizine may have a weak effect on seizure frequency but had a significant withdrawal rate, probably due to adverse effects, and should not be recommended for use as an add-on treatment. Similarly, there is no convincing evidence to support the use of nifedipine or nimodipine as add-on treatments for epilepsy.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-02-19 15:50:58 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2013-02-19 14:22:16 +0000" MODIFIED_BY="[Empty name]">
<P>This review is an update of a previously published review in the Cochrane Database of Systematic Reviews (<I>The Cochrane Library</I> 2001, Issue 4) on 'Calcium antagonists as an add-on therapy for drug-resistant epilepsy'. The purpose of this review was to include studies that examined the use of calcium channel antagonists in conjunction with other antiepileptic medications in order to reduce the number of seizures experienced by individuals with epilepsy refractory to first line medications.</P>
<CONDITION MODIFIED="2013-02-19 14:21:03 +0000" MODIFIED_BY="[Empty name]">
<P>Epilepsy is a chronic neurological condition that results in recurrent spontaneous seizures. The diagnosis is primarily clinical and relies upon taking a history from the patient and eye witnesses about the nature and number of seizures; an electroencephalogram (EEG) can supplement the diagnosis (<LINK REF="REF-Smith-2005" TYPE="REFERENCE">Smith 2005</LINK>) and brain imaging might identify the cause. For up to 70% of patients, seizures are controlled with antiepileptic medication. A number of factors have been shown to influence prognosis including gender, treatment history, age, total number of seizures and time from first seizure (<LINK REF="REF-Bonnett-2012" TYPE="REFERENCE">Bonnett 2012</LINK>). For around 30% of patients, seizures continue despite treatment and these patients often experience adverse effects, neuropsychological problems and poor quality of life.</P>
</CONDITION>
<INTERVENTION MODIFIED="2013-02-19 14:21:04 +0000" MODIFIED_BY="[Empty name]">
<P>Epilepsy can be treated with a number of medications. They are under the umbrella name of 'antiepileptic drugs' (AEDs) but are actually drugs of differing mechanisms which have been shown to be effective in reducing the number of seizures (<LINK REF="REF-Nunes-2012" TYPE="REFERENCE">Nunes 2012</LINK>). Calcium antagonists can be used as an add-on treatment with AEDs. They can be administered in tablet form.</P>
</INTERVENTION>
<THEORY MODIFIED="2013-02-19 14:22:15 +0000" MODIFIED_BY="[Empty name]">
<P>Abnormalities of the P/Q calcium channel have been implicated in epilepsy (<LINK REF="REF-Jouvenceau-2001" TYPE="REFERENCE">Jouvenceau 2001</LINK>) and calcium channel antagonists block these channels (<LINK REF="REF-Triggle-2007" TYPE="REFERENCE">Triggle 2007</LINK>), potentially preventing the occurrence of seizures. Verapamil, one of the calcium antagonists, has an additional putative mechanism in that it inhibits P-glycoprotein, which is a drug transporter that might pump antiepileptic drugs out of the brain and away from the site of action (<LINK REF="REF-Summers-2004" TYPE="REFERENCE">Summers 2004</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2013-02-19 14:22:16 +0000" MODIFIED_BY="[Empty name]">
<P>Epilepsy specialists are likely to encounter patients with drug-resistant epilepsy. As such, providing them with an up to date guide to clinical trials measuring the effect of calcium channel antagonists as add-on therapy will help guide the decision making process.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2013-02-19 14:22:17 +0000" MODIFIED_BY="[Empty name]">
<P>To evaluate the effects of calcium antagonists when used as add-on therapy for people with drug-resistant epilepsy.</P>
</OBJECTIVES>
<METHODS MODIFIED="2013-02-19 15:11:50 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2013-02-19 14:24:14 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2013-02-19 14:22:34 +0000" MODIFIED_BY="[Empty name]">
<P>We included studies that were:<BR/>(a) randomised controlled trials (RCTs) using an adequate method of randomisation;<BR/>(b) double, single or unblinded trials;<BR/>(c) placebo controlled;<BR/>(d) parallel group or cross-over studies;<BR/>(e) active controlled i.e. 'head to head' trials.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2013-02-19 14:22:40 +0000" MODIFIED_BY="[Empty name]">
<P>Individuals of any age with drug-resistant epilepsy.</P>
<P>As there is no internationally accepted definition of drug-resistant epilepsy, for the purpose of this review we considered individuals to be drug-resistant if they had failed to respond to a minimum of two AEDs given as monotherapy.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2012-11-21 11:59:36 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>The study treatment group received a calcium antagonist in addition to their current conventional antiepileptic drug treatment (i.e. add-on treatment) for a minimum period of eight weeks.</LI>
<LI>The control group received a placebo in addition to their current conventional antiepileptic drug treatment for a minimum period of eight week; or</LI>
<LI>The control group received a differing calcium antagonist to their current conventional antiepileptic drug treatment for a minimum period of eight weeks.</LI>
</OL>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-02-19 14:24:14 +0000" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2013-02-19 14:23:49 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">50% or greater reduction in seizure frequency</HEADING>
<P>The proportion of individuals with a 50% or greater reduction in seizure frequency in the treatment period compared with the pre-randomisation baseline period was chosen as our primary outcome. This outcome is commonly reported in this type of study, and can be calculated for studies that do not report this outcome provided that baseline seizure data were recorded.</P>
</SUBSECTION>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2013-02-19 14:24:14 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">Treatment withdrawal</HEADING>
<P>The proportion of individuals having treatment (calcium antagonist, placebo or other active calcium antagonist) withdrawn during the treatment period was used as a global measure of tolerability. However, in studies of short duration treatment withdrawal is more likely to be due to adverse effects than lack of efficacy.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse effects</HEADING>
<UL>
<LI>Proportion of individuals experiencing any of the following five adverse effects, which we considered to be common and important adverse effects of AEDs:</LI>
<OL>
<LI>ataxia;</LI>
<LI>dizziness;</LI>
<LI>fatigue (asthenia);</LI>
<LI>nausea;</LI>
<LI>somnolence.</LI>
</OL>
<LI>The proportion of individuals experiencing the five most common adverse effects, if different from the above (also see methods section).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Cognitive effects</HEADING>
<P>The differences between overall cognition scores, including scores reported of cognitive domains such as:</P>
<OL>
<LI>attention;</LI>
<LI>executive function;</LI>
<LI>language;</LI>
<LI>memory;</LI>
<LI>visuo-spatial.</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Quality of life</HEADING>
<P>The differences between overall quality of life scores, including scores reported for quality of life domains such as:</P>
<OL>
<LI>social function;</LI>
<LI>seizure worry;</LI>
<LI>emotional well-being;</LI>
<LI>energy or fatigue;</LI>
<LI>medication effects.</LI>
</OL>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-02-19 14:24:24 +0000" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2013-02-19 14:24:23 +0000" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Epilepsy Group Specialized Register (29 January 2013). In addition, we searched the following databases.</P>
<P>(a) Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> 2012, Issue 12 of 12) using the search strategy outlined in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>;</P>
<P>(b) MEDLINE (Ovid) (1948 to 29 January 2013) using the search strategy outlined in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>;</P>
<P>(c) SCOPUS (all years to 29 January 2013) using the search strategy outlined in <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>.</P>
<P>There were no language restrictions.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2013-02-19 14:24:24 +0000" MODIFIED_BY="[Empty name]">
<P>We reviewed the reference lists of included studies to search for additional reports of relevant studies.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2013-02-19 15:11:50 +0000" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2013-02-19 14:26:48 +0000" MODIFIED_BY="[Empty name]">
<P>Two review authors (MH and JP) independently assessed articles for inclusion. Any disagreements were resolved through mutual discussion; failing this, a third party opinion was sought. The same review authors independently carried out data extraction and assessed risk of bias. Again, disagreements were resolved by mutual discussion and failing this a third party opinion was sought.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2013-02-19 15:11:50 +0000" MODIFIED_BY="[Empty name]">
<P>The following information was extracted for each trial using a data extraction sheet.</P>
<SUBSECTION>
<HEADING LEVEL="5">Methodological/trial design</HEADING>
<OL>
<LI>Method of randomisation and allocation concealment</LI>
<LI>Method of blinding</LI>
<LI>Number of people excluded from reported analyses</LI>
<LI>Duration of baseline period</LI>
<LI>Duration of treatment period</LI>
<LI>Dose(s) of each calcium antagonist tested</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Individual participant/demographic information</HEADING>
<OL>
<LI>Total number of participants allocated to each treatment group</LI>
<LI>Age and gender</LI>
<LI>Number of participants with partial or generalized epilepsy</LI>
<LI>Seizure types.</LI>
<LI>Seizure frequency during the baseline period.</LI>
<LI>Number of background drugs.</LI>
</OL>
<P>Where necessary, we contacted original authors to confirm the following information.</P>
<OL>
<LI>The method of randomisation.</LI>
<LI>The total number randomised to each group.</LI>
<LI>The number of participants in each group achieving a 50% or greater reduction in seizure frequency per treatment group.</LI>
<LI>The number of participants having treatment withdrawn post-randomisation per treatment group.</LI>
<LI>For those excluded:</LI>
</OL>
<UL>
<UL>
<LI>the reason for exclusion;</LI>
<LI>whether any of those excluded completed the treatment phase;</LI>
<LI>whether any of those excluded had a 50% or greater reduction in seizure frequency during the treatment phase.</LI>
</UL>
</UL>
</SUBSECTION>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2013-02-19 14:29:14 +0000" MODIFIED_BY="[Empty name]">
<P>Two review authors independently made an assessment of the risk of bias for each trial using the Cochrane risk of bias table as described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2010" TYPE="REFERENCE">Higgins 2010</LINK>). Any disagreements were discussed and resolved. Included studies were rated as adequate, inadequate or unclear on six domains applicable to randomised controlled trials: randomisation method, allocation concealment, blinding methods, incomplete outcome data, selective outcome reporting, and other sources of bias. Summary of findings tables were created where the GRADE approach for assessing quality of evidence was employed.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2013-02-19 14:29:43 +0000" MODIFIED_BY="[Empty name]">
<P>The primary outcome of seizure reduction was presented as a risk ratio. Secondary outcomes including treatment withdrawal and adverse effects were presented as risk ratios. The secondary outcomes of cognition and quality of life were to be presented as the standardised mean difference (SMD).</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2013-02-19 14:29:54 +0000" MODIFIED_BY="[Empty name]">
<P>A range of cognitive and quality of life measures were likely to be utilised in trials. If measures differed across studies, the standardised mean difference would take into account this variance. Cognitive outcome is also likely to vary and close examination of outcomes was to be carried out to ensure the appropriate combination of study data.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2013-02-19 14:29:56 +0000" MODIFIED_BY="[Empty name]">
<P>Any missing data were sought from the study authors. We carried out intention-to-treat, best case and worst case analysis to account for any missing data. All analyses are presented in the main report.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2013-02-19 14:30:14 +0000" MODIFIED_BY="[Empty name]">
<P>Clinical heterogeneity was assessed by comparing the distribution of important individual participant factors among trials (for example age, seizure type, duration of epilepsy, number of AEDs taken at the time of randomisation) and trial factors (for example randomisation concealment, blinding, losses to follow-up). Statistical heterogeneity was examined using a Chi<SUP>2</SUP> test and the I<SUP>2</SUP> statistic for heterogeneity and, providing no significant heterogeneity was present (P &gt; 0.1), we employed a fixed-effect model. In the event heterogeneity was found, a random-effects model analysis was planned using the inverse variance method.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2013-02-19 14:30:17 +0000" MODIFIED_BY="[Empty name]">
<P>All protocols were requested from study authors to enable comparison of outcomes of interest.</P>
<P>Reporting biases, such as publication bias, were examined by identifying certain aspects of each study (for example sponsors of the research, research teams involved). We intended to examine funnel plots in the event an appropriate number of studies were able to be combined.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2013-02-19 14:30:40 +0000" MODIFIED_BY="[Empty name]">
<P>A fixed-effect model meta-analysis was employed to synthesise the data. Comparisons we expected to carry out included:</P>
<OL>
<LI>intervention group versus controls on seizure reduction;</LI>
<LI>intervention group versus controls on treatment withdrawal;</LI>
<LI>intervention group versus controls on adverse effects;</LI>
<LI>intervention group versus controls on cognitive outcome;</LI>
<LI>intervention group versus controls on quality of life.</LI>
</OL>
<P>Each comparison was to be stratified by type of control group, that is placebo or active control, and study characteristics to ensure the appropriate combination of study data.</P>
<P>Our preferred estimator was the Mantel-Haenzsel risk ratio (RR). For the outcomes 50% or greater reduction in seizure frequency and treatment withdrawal, we used 95% confidence intervals (CIs). For individual adverse effects we used 99% CIs to make an allowance for multiple testing.</P>
<P>Our analyses included all participants in the treatment group to which they had been allocated. For the efficacy outcome (50% or greater reduction in seizure frequency) we undertook three analyses.</P>
<OL>
<LI>Primary (intention-to-treat (ITT)) analysis: participants not completing follow-up or with inadequate seizure data were assumed non-responders. To test the effect of this assumption, we undertook the following sensitivity analyses. Analysis by ITT was done where this was reported by the included studies.</LI>
<LI>Worst case analysis: participants not completing follow-up or with inadequate seizure data were assumed to be non-responders in the calcium antagonist group, and responders in the placebo group.</LI>
<LI>Best case analysis: participants not completing follow-up or with inadequate seizure data were assumed to be responders in the calcium antagonist group, and non-responders in the placebo group.</LI>
</OL>
<P>Data from cross-over and parallel studies were not combined together in meta-analyses due to the high possibility of carry-over or period effects. Within the included cross-over studies it was difficult to rule out the existence of this bias. Half of the studies (<LINK REF="STD-Battaglia-1991" TYPE="STUDY">Battaglia 1991</LINK>; <LINK REF="STD-Fr_x00f6_scher-1988" TYPE="STUDY">Fröscher 1988</LINK>; <LINK REF="STD-Keene-1989" TYPE="STUDY">Keene 1989</LINK>; <LINK REF="STD-Moglia-1986" TYPE="STUDY">Moglia 1986</LINK>; <LINK REF="STD-Overweg-1984" TYPE="STUDY">Overweg 1984</LINK>; <LINK REF="STD-Pelliccia-1993" TYPE="STUDY">Pelliccia 1993</LINK>; <LINK REF="STD-Starreveld-1989" TYPE="STUDY">Starreveld 1989</LINK> reported either no washout period or a very short one (two weeks), and only three of the 11 studies (<LINK REF="STD-Alving-1989" TYPE="STUDY">Alving 1989</LINK>; <LINK REF="STD-Battaglia-1991" TYPE="STUDY">Battaglia 1991</LINK>; <LINK REF="STD-Starreveld-1989" TYPE="STUDY">Starreveld 1989</LINK>) performed any statistical analysis to test for the existence of a carry-over or period effect. Therefore, the choice was taken not to combine the data in a meta-analysis.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2012-06-01 08:47:39 +0100" MODIFIED_BY="[Empty name]">
<P>Subgroup analysis was undertaken for adverse effects. We intended to investigate heterogeneity using sensitivity analysis if deemed appropriate.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2012-06-01 08:48:17 +0100" MODIFIED_BY="[Empty name]">
<P>We also intended to carry out sensitivity analysis if peculiarities were found between study quality, characteristics of participants, interventions and outcomes.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-02-19 14:33:47 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2013-02-19 14:31:31 +0000" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2013-02-19 14:30:50 +0000" MODIFIED_BY="[Empty name]">
<P>The search revealed 422 records identified from the databases outlined in <LINK TAG="ELECTRONIC_SEARCHES" TYPE="SECTION">Electronic searches</LINK>. Three hundred and two records remained after duplicates were removed, all were screened for inclusion in the review. Two hundred and eighty-three records were excluded at this point leaving 19 full-text articles to be assessed for eligibility. Following this seven trials were excluded (see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> and <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> for reasons for exclusion). A total of 11 studies were included in the review.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2013-02-19 14:31:17 +0000" MODIFIED_BY="[Empty name]">
<P>There were eight trials included which compared the calcium antagonist flunarizine to placebo, two trials which compared nimodipine to placebo, and one trial which compared nifedipine to placebo. Overall a total of 424 patients with drug-resistant epilepsy took part in the 11 trials.</P>
<P>Eight trials (representing 363 individuals) compared flunarizine with placebo (<LINK REF="STD-Alving-1989" TYPE="STUDY">Alving 1989</LINK>; <LINK REF="STD-Battaglia-1991" TYPE="STUDY">Battaglia 1991</LINK>; <LINK REF="STD-Fr_x00f6_scher-1988" TYPE="STUDY">Fröscher 1988</LINK>; <LINK REF="STD-Keene-1989" TYPE="STUDY">Keene 1989</LINK>; <LINK REF="STD-Moglia-1986" TYPE="STUDY">Moglia 1986</LINK>; <LINK REF="STD-Overweg-1984" TYPE="STUDY">Overweg 1984</LINK>; <LINK REF="STD-Pledger-1994" TYPE="STUDY">Pledger 1994</LINK>; <LINK REF="STD-Starreveld-1989" TYPE="STUDY">Starreveld 1989</LINK>). <LINK REF="STD-Pledger-1994" TYPE="STUDY">Pledger 1994</LINK> was a parallel-group trial recruiting 93 individuals and provided data for all outcomes investigated in this review. The remaining seven trials were cross-over trials, however we were unable to obtain data from the first treatment phase for 50% reduction in seizure frequency or adverse effects. Data for treatment withdrawal were available from only three of these seven cross-over trials (<LINK REF="STD-Fr_x00f6_scher-1988" TYPE="STUDY">Fröscher 1988</LINK>; <LINK REF="STD-Keene-1989" TYPE="STUDY">Keene 1989</LINK>; <LINK REF="STD-Moglia-1986" TYPE="STUDY">Moglia 1986</LINK>) (247 individuals). In view of this difficulty, we decided to summarize the reported results of all of the cross-over trials meeting our inclusion criteria in tables and in the text of this review.</P>
<P>The trial comparing nifedipine to placebo (<LINK REF="STD-Larkin-1992" TYPE="STUDY">Larkin 1992</LINK>) was a cross-over trial that recruited 22 individuals. Although 50% or greater reduction in seizure frequency, treatment withdrawal and adverse effects were reported we were unable to acquire data for the first treatment period. As for the flunarizine trials, results of this trial are presented in tables.</P>
<P>The two trials that compared nimodipine with placebo (<LINK REF="STD-Larkin-1991" TYPE="STUDY">Larkin 1991</LINK>; <LINK REF="STD-Pelliccia-1993" TYPE="STUDY">Pelliccia 1993</LINK>) were also cross-over trials and recruited a total of 39 individuals. We were able to obtain data for the first treatment phase from only one of these trials (<LINK REF="STD-Pelliccia-1993" TYPE="STUDY">Pelliccia 1993</LINK>) (17 individuals) for the outcomes investigated in this review. For the other trial (<LINK REF="STD-Larkin-1991" TYPE="STUDY">Larkin 1991</LINK>) we were unable to obtain data from the first treatment period. We have tabulated the reported results of both cross-over trials.<BR/>
</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2013-02-19 14:31:31 +0000" MODIFIED_BY="[Empty name]">
<P>We excluded seven trials. <LINK REF="STD-Cavazzuti-1986" TYPE="STUDY">Cavazzuti 1986</LINK> was a cross-over trial (14 individuals) that compared flunarizine with placebo. We excluded this trial because some participants received the study medication for less than eight weeks. The other three excluded trials (195 individuals) compared nimodipine with placebo (<LINK REF="STD-Malashkhia-1996" TYPE="STUDY">Malashkhia 1996</LINK>; <LINK REF="STD-Meyer-1995" TYPE="STUDY">Meyer 1995</LINK>; <LINK REF="STD-Sasso-1993" TYPE="STUDY">Sasso 1993</LINK>). One trial (<LINK REF="STD-Malashkhia-1996" TYPE="STUDY">Malashkhia 1996</LINK>) gradually tapered off all previous AEDs then randomised individuals into phenobarbital plus nimodipine or phenobarbital alone, and the other two trials (<LINK REF="STD-Meyer-1995" TYPE="STUDY">Meyer 1995</LINK>; <LINK REF="STD-Sasso-1993" TYPE="STUDY">Sasso 1993</LINK>) did not investigate 50% or greater reduction in seizure frequency. <LINK REF="STD-Binnie-1985" TYPE="STUDY">Binnie 1985</LINK> did not have a randomisation process and included patients from three arms of a previous study. <LINK REF="STD-Handforth-1995" TYPE="STUDY">Handforth 1995</LINK> was an open-label extension study and <LINK REF="STD-Treiman-1993" TYPE="STUDY">Treiman 1993</LINK> was a non-randomised concentration-controlled study.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2013-02-19 14:33:02 +0000" MODIFIED_BY="[Empty name]">
<P>See <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> for a summary of the risk of bias in the included studies.</P>
<ALLOCATION MODIFIED="2013-02-19 14:32:35 +0000" MODIFIED_BY="[Empty name]">
<P>The method of randomisation used by <LINK REF="STD-Pledger-1994" TYPE="STUDY">Pledger 1994</LINK> was a computer-generated stratified random list. Concealment of allocation was achieved by giving that list to an unblinded pharmacist, who dispensed consecutive blinded treatments accordingly. For one trial (<LINK REF="STD-Pelliccia-1993" TYPE="STUDY">Pelliccia 1993</LINK>), individuals were allocated alternately to one treatment or the other, a method of allocation concealment that has a recognizable pattern and is not truly random. We assigned an unclear risk of bias to it.</P>
<P>Treatment allocation and allocation concealment methods were not described for the remaining trials (<LINK REF="STD-Alving-1989" TYPE="STUDY">Alving 1989</LINK>; <LINK REF="STD-Battaglia-1991" TYPE="STUDY">Battaglia 1991</LINK>; <LINK REF="STD-Fr_x00f6_scher-1988" TYPE="STUDY">Fröscher 1988</LINK>; <LINK REF="STD-Keene-1989" TYPE="STUDY">Keene 1989</LINK>; <LINK REF="STD-Larkin-1991" TYPE="STUDY">Larkin 1991</LINK>; <LINK REF="STD-Larkin-1992" TYPE="STUDY">Larkin 1992</LINK>; <LINK REF="STD-Moglia-1986" TYPE="STUDY">Moglia 1986</LINK>; <LINK REF="STD-Overweg-1984" TYPE="STUDY">Overweg 1984</LINK>; <LINK REF="STD-Starreveld-1989" TYPE="STUDY">Starreveld 1989</LINK>). The authors were contacted by previous writers of this review, however no response was received.</P>
</ALLOCATION>
<BLINDING MODIFIED="2013-02-19 14:32:48 +0000" MODIFIED_BY="[Empty name]">
<P>Six of the trials were blinded by using matching placebo and active treatment (<LINK REF="STD-Alving-1989" TYPE="STUDY">Alving 1989</LINK>; <LINK REF="STD-Fr_x00f6_scher-1988" TYPE="STUDY">Fröscher 1988</LINK>; <LINK REF="STD-Keene-1989" TYPE="STUDY">Keene 1989</LINK>; <LINK REF="STD-Larkin-1991" TYPE="STUDY">Larkin 1991</LINK>; <LINK REF="STD-Larkin-1992" TYPE="STUDY">Larkin 1992</LINK>; <LINK REF="STD-Pelliccia-1993" TYPE="STUDY">Pelliccia 1993</LINK>). This was graded as being adequate blinding for both key personnel and the patients involved, but no information was provided as to how outcome assessors were blinded and as such it was graded as at unclear risk of bias. The methods of blinding in the remaining trials (<LINK REF="STD-Battaglia-1991" TYPE="STUDY">Battaglia 1991</LINK>; <LINK REF="STD-Moglia-1986" TYPE="STUDY">Moglia 1986</LINK>; <LINK REF="STD-Overweg-1984" TYPE="STUDY">Overweg 1984</LINK>; <LINK REF="STD-Starreveld-1989" TYPE="STUDY">Starreveld 1989</LINK>) were not described and they were graded as having an unclear risk of bias for key study personnel, patients and outcome assessors.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2013-02-19 14:32:58 +0000" MODIFIED_BY="[Empty name]">
<P>Ten of the trials reported attrition but did not perform an intention-to-treat analysis (<LINK REF="STD-Alving-1989" TYPE="STUDY">Alving 1989</LINK>; <LINK REF="STD-Battaglia-1991" TYPE="STUDY">Battaglia 1991</LINK>; <LINK REF="STD-Fr_x00f6_scher-1988" TYPE="STUDY">Fröscher 1988</LINK>; <LINK REF="STD-Larkin-1991" TYPE="STUDY">Larkin 1991</LINK>; <LINK REF="STD-Larkin-1992" TYPE="STUDY">Larkin 1992</LINK>; <LINK REF="STD-Moglia-1986" TYPE="STUDY">Moglia 1986</LINK>; <LINK REF="STD-Overweg-1984" TYPE="STUDY">Overweg 1984</LINK>; <LINK REF="STD-Pelliccia-1993" TYPE="STUDY">Pelliccia 1993</LINK>; <LINK REF="STD-Pledger-1994" TYPE="STUDY">Pledger 1994</LINK>; <LINK REF="STD-Starreveld-1989" TYPE="STUDY">Starreveld 1989</LINK>). Certain studies (<LINK REF="STD-Alving-1989" TYPE="STUDY">Alving 1989</LINK>; <LINK REF="STD-Battaglia-1991" TYPE="STUDY">Battaglia 1991</LINK>; <LINK REF="STD-Fr_x00f6_scher-1988" TYPE="STUDY">Fröscher 1988</LINK>; <LINK REF="STD-Larkin-1991" TYPE="STUDY">Larkin 1991</LINK>; <LINK REF="STD-Moglia-1986" TYPE="STUDY">Moglia 1986</LINK>; <LINK REF="STD-Overweg-1984" TYPE="STUDY">Overweg 1984</LINK>; <LINK REF="STD-Pelliccia-1993" TYPE="STUDY">Pelliccia 1993</LINK>) lost a significant number of patients and not performing an intention-to-treat analysis subjected them to a high risk of bias. <LINK REF="STD-Larkin-1992" TYPE="STUDY">Larkin 1992</LINK> lost a small percentage of patients and not performing an intention-to-treat analysis would not have impacted the findings significantly. Two trials (<LINK REF="STD-Keene-1989" TYPE="STUDY">Keene 1989</LINK>; <LINK REF="STD-Pledger-1994" TYPE="STUDY">Pledger 1994</LINK>) contained no missing data and thus intention-to-treat analysis was not deemed necessary, and these trials were graded as having a low risk of bias.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2013-02-19 14:33:02 +0000" MODIFIED_BY="[Empty name]">
<P>The studies by <LINK REF="STD-Fr_x00f6_scher-1988" TYPE="STUDY">Fröscher 1988</LINK>; <LINK REF="STD-Keene-1989" TYPE="STUDY">Keene 1989</LINK>; <LINK REF="STD-Overweg-1984" TYPE="STUDY">Overweg 1984</LINK>; and <LINK REF="STD-Starreveld-1989" TYPE="STUDY">Starreveld 1989</LINK> did not include the first phase data from their trials thus posing a high risk of reporting bias for both primary and secondary outcomes. As for <LINK REF="STD-Moglia-1986" TYPE="STUDY">Moglia 1986</LINK>, the results reported were regarding the overall incidence of seizure and certain side effects of the medication. This meant a deviation from the primary outcome 50% reduction in seizures. The secondary outcomes were incomplete and no figures were presented.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2012-05-23 15:15:21 +0100" MODIFIED_BY="[Empty name]">
<P>No other biases were detected in the included studies. </P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2013-02-19 14:33:47 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Studies comparing flunarizine to placebo</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">A 50% or greater reduction in seizure frequency</HEADING>
<P>Data for this outcome were only provided from one trial (<LINK REF="STD-Pledger-1994" TYPE="STUDY">Pledger 1994</LINK>).</P>
<P>(i) Intention-to-treat analysis<BR/>The RR for this study was 1.53 (95% CI 0.59 to 3.96) indicating a non-significant advantage for flunarizine.</P>
<P>(ii) Best case and worst case scenarios<BR/>As no individuals were excluded from analyses, we did not undertake any best and worst case analyses.</P>
<P>We were unable to acquire the data for this outcome for the first treatment phase from the other seven cross-over trials (<LINK REF="STD-Alving-1989" TYPE="STUDY">Alving 1989</LINK>; <LINK REF="STD-Battaglia-1991" TYPE="STUDY">Battaglia 1991</LINK>; <LINK REF="STD-Fr_x00f6_scher-1988" TYPE="STUDY">Fröscher 1988</LINK>; <LINK REF="STD-Keene-1989" TYPE="STUDY">Keene 1989</LINK>; <LINK REF="STD-Moglia-1986" TYPE="STUDY">Moglia 1986</LINK>; <LINK REF="STD-Overweg-1984" TYPE="STUDY">Overweg 1984</LINK>; <LINK REF="STD-Starreveld-1989" TYPE="STUDY">Starreveld 1989</LINK>). Although all the studies reported a 50% or greater reduction in seizure frequency on flunarizine compared with placebo, only two studies (<LINK REF="STD-Alving-1989" TYPE="STUDY">Alving 1989</LINK>; <LINK REF="STD-Overweg-1984" TYPE="STUDY">Overweg 1984</LINK>) showed a statistically significant reduction. The remaining trials did not report a statistical analysis for this outcome. Some of the cross-over trials reported the overall reduction in seizure frequency on flunarizine compared with placebo. In four trials no significant difference was found (<LINK REF="STD-Alving-1989" TYPE="STUDY">Alving 1989</LINK>; <LINK REF="STD-Battaglia-1991" TYPE="STUDY">Battaglia 1991</LINK>; <LINK REF="STD-Fr_x00f6_scher-1988" TYPE="STUDY">Fröscher 1988</LINK>; <LINK REF="STD-Starreveld-1989" TYPE="STUDY">Starreveld 1989</LINK>). In one cross-over trial no statistical analysis was reported (<LINK REF="STD-Keene-1989" TYPE="STUDY">Keene 1989</LINK>) but eight people taking placebo had a 50% or greater reduction in seizure frequency compared with five on flunarizine. In the remaining trial (<LINK REF="STD-Moglia-1986" TYPE="STUDY">Moglia 1986</LINK>), a statistically significant reduction (P = 0.001) in seizure frequency was found but the effect was small. For example, in individuals allocated placebo in the first treatment period and flunarizine in the second, the mean monthly seizure frequency on placebo was 5.13, which dropped to 3.56 on flunarizine. We have summarized the results of individual trials in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Treatment withdrawal</HEADING>
<P>We had data for this outcome from four trials (<LINK REF="STD-Fr_x00f6_scher-1988" TYPE="STUDY">Fröscher 1988</LINK>; <LINK REF="STD-Keene-1989" TYPE="STUDY">Keene 1989</LINK>; <LINK REF="STD-Moglia-1986" TYPE="STUDY">Moglia 1986</LINK>; <LINK REF="STD-Pledger-1994" TYPE="STUDY">Pledger 1994</LINK>). A Chi<SUP>2</SUP> test for heterogeneity suggested no significant statistical heterogeneity (Chi<SUP>2</SUP> = 0.04, df = 1, P = 0.84). Individuals were significantly more likely to have flunarizine withdrawn than placebo, and the RR for treatment withdrawal was 7.11 95% CI 1.73 to 29.30). We were unable to obtain data for this outcome from the first treatment period of four cross-over trials (<LINK REF="STD-Alving-1989" TYPE="STUDY">Alving 1989</LINK>; <LINK REF="STD-Battaglia-1991" TYPE="STUDY">Battaglia 1991</LINK>; <LINK REF="STD-Overweg-1984" TYPE="STUDY">Overweg 1984</LINK>; <LINK REF="STD-Starreveld-1989" TYPE="STUDY">Starreveld 1989</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse effects</HEADING>
<P>We were unable to obtain data from the first treatment period of the cross-over trials, hence we were only able to analyse data from one trial (<LINK REF="STD-Pledger-1994" TYPE="STUDY">Pledger 1994</LINK>). In addition to reports of dizziness, fatigue and nausea (vomiting), the five most common adverse effects were altered concentration, blurred vision, diplopia (double vision), irritability and insomnia, and these were included in our analysis. All these adverse effects were associated with flunarizine. However, their 99% CIs included unity indicating no statistical significance: altered concentration RR 2.38 (99% CI 0.44 to 12.99); blurred vision RR 4.09 (99% CI 0.85 to 19.73); diplopia RR 1.63 (99% CI 0.42 to 6.42); dizziness RR 1.82 (99% CI 0.72 to 4.61); fatigue RR 1.66 (99% CI 0.59 to 4.64); irritability RR 3.07 (99% CI 0.60 to 15.68); vomiting RR 4.09 (99% CI 0.57 to 29.16), and insomnia RR 2.72 (99% CI 0.52 to 14.33). In the cross-over trials, various adverse effects were reported but none were reported as being significantly associated with flunarizine. We summarized these results in <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Study comparing nifedipine to placebo</HEADING>
<P>Nifedipine was compared with placebo in one cross-over trial (<LINK REF="STD-Larkin-1992" TYPE="STUDY">Larkin 1992</LINK>) in which 22 participants were recruited. For this trial we were unable to obtain data from the first treatment period on 50% or greater reduction in seizure frequency or adverse effects. The trialists did report 50% or greater reduction in seizure frequency and no significant difference between nifedipine and placebo was found. Similarly, no adverse effects were significantly associated with nifedipine. Results are summarized in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> and <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>. No individuals had treatment withdrawn while taking nifedipine and one person had placebo withdrawn.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Studies comparing nimodipine to placebo</HEADING>
<P>Of the two cross-over trials comparing nimodipine and placebo (<LINK REF="STD-Larkin-1991" TYPE="STUDY">Larkin 1991</LINK>; <LINK REF="STD-Pelliccia-1993" TYPE="STUDY">Pelliccia 1993</LINK>), we were able to obtain data from the first treatment period for only one (<LINK REF="STD-Pelliccia-1993" TYPE="STUDY">Pelliccia 1993</LINK>), which recruited 17 participants. <LINK REF="STD-Larkin-1991" TYPE="STUDY">Larkin 1991</LINK> reported an analysis for 50% or greater reduction in seizure frequency, adverse effects and treatment withdrawal, but data for the first treatment period were not available.</P>
<SUBSECTION>
<HEADING LEVEL="4">50% or greater reduction in seizure frequency</HEADING>
<P>(i) Intention-to-treat analysis</P>
<P>Three of eight participants allocated flunarizine and none of those allocated placebo had a 50% or greater reduction in seizure frequency. This gave a RR of 7.78 (99% CI 0.46 to 130.88) suggesting an advantage for nimodipine. However, given the small number of individuals recruited into this trial, the data were insufficient to conclude with confidence that nimodipine had an effect on seizure frequency.</P>
<P>This outcome was investigated in the cross-over trial reported by <LINK REF="STD-Larkin-1991" TYPE="STUDY">Larkin 1991</LINK> and no significant difference between nimodipine and placebo was found (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
<P>(ii) Best case and worst case scenarios</P>
<P>As no participants were excluded from analyses, we did not undertake any best and worst case analyses.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Treatment withdrawal</HEADING>
<P>Two of eight participants allocated nimodipine and one of nine allocated placebo had treatment withdrawn. This gave a RR of 2.25 (99% CI 0.25 to 20.38) suggesting a higher but non-significant withdrawal rate on nimodipine.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse effects</HEADING>
<P>The adverse effects reported in this trial were ataxia, dystonia, hypotension, irritability, somnolence and tremor. Each adverse effect was experienced by one of eight participants allocated to the nimodipine group but by none of the individuals allocated to placebo. The number of individuals recruited into this trial and the number experiencing adverse effects were too small to allow any firm conclusions about the adverse effects associated with nimodipine.</P>
<P>In the trial by <LINK REF="STD-Larkin-1991" TYPE="STUDY">Larkin 1991</LINK>, no adverse effects significantly associated with nimodipine were reported. Results are summarized in <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2013-02-19 15:11:03 +0000" MODIFIED_BY="[Empty name]">
<P>On the whole the trials included in this review were small, the largest being a parallel-group trial (<LINK REF="STD-Pledger-1994" TYPE="STUDY">Pledger 1994</LINK>) recruiting 93 participants while the remainder were two-period cross-over trials recruiting between 17 and 90 participants. The descriptions of important methodology in the trial reports were poor. One trial report described a method of allocation concealment which was adequate (<LINK REF="STD-Pledger-1994" TYPE="STUDY">Pledger 1994</LINK>), while a second described a method which was inadequate (<LINK REF="STD-Pelliccia-1993" TYPE="STUDY">Pelliccia 1993</LINK>) leaving the trial subject to bias. For the remaining nine trials, the method of allocation concealment was not described and the authors have not responded to our correspondence asking for clarification. We are therefore left uncertain as to whether nine of the 11 included trials had been subject to allocation bias. All the trials were double-blinded and placebo controlled. For seven trials (<LINK REF="STD-Alving-1989" TYPE="STUDY">Alving 1989</LINK>; <LINK REF="STD-Fr_x00f6_scher-1988" TYPE="STUDY">Fröscher 1988</LINK>; <LINK REF="STD-Keene-1989" TYPE="STUDY">Keene 1989</LINK>; <LINK REF="STD-Larkin-1991" TYPE="STUDY">Larkin 1991</LINK>; <LINK REF="STD-Larkin-1992" TYPE="STUDY">Larkin 1992</LINK>; <LINK REF="STD-Pelliccia-1993" TYPE="STUDY">Pelliccia 1993</LINK>; <LINK REF="STD-Pledger-1994" TYPE="STUDY">Pledger 1994</LINK>) adequate blinding methods were described, whereas methods were not described for the other four trials (<LINK REF="STD-Battaglia-1991" TYPE="STUDY">Battaglia 1991</LINK>; <LINK REF="STD-Moglia-1986" TYPE="STUDY">Moglia 1986</LINK>; <LINK REF="STD-Overweg-1984" TYPE="STUDY">Overweg 1984</LINK>; <LINK REF="STD-Starreveld-1989" TYPE="STUDY">Starreveld 1989</LINK>).</P>
<P>The majority of the trials included in this review were cross-over trials. The use of cross-over trials in this scenario is questionable, particularly for flunarizine which has an elimination half life of around 18 days (<LINK REF="REF-Reynolds-1993" TYPE="REFERENCE">Reynolds 1993</LINK>). Furthermore, flunarizine was still detected in the serum four months after taking the last dose of this drug in four of nine participants allocated to the sequence of flunarizine then placebo in one of the trials included in this review (<LINK REF="STD-Fr_x00f6_scher-1988" TYPE="STUDY">Fröscher 1988</LINK>). It is therefore likely that the cross-over trials included in this review have been subject to carry-over effects. On the whole, this would lead to an underestimate of the effect of flunarizine, nifedipine and nimodipine on seizures, and an underestimate of the occurrence of their adverse effects. The analysis we proposed in this review, using the first treatment period as a parallel-group trial, would not have been subject to this bias. However, for the majority of trials we were unable to acquire the required data.</P>
<P>For our primary outcome, 50% or greater reduction in seizure frequency, flunarizine was found to be significantly better than placebo in two out of seven cross-over trials, while the parallel-group trial found no significant difference. Due to difficulties obtaining data from the first treatment period from the cross-over trials, we were unable to undertake a meta-analysis. The overall results of these trials do not provide convincing evidence of an effect of flunarizine on seizure frequency, and the estimates of effect are on the whole small. Similarly we have found no convincing evidence of an effect on seizure frequency for nifedipine and nimodipine.</P>
<P>For our outcome treatment withdrawal, flunarizine was seven times more likely to be withdrawn than placebo. The adverse effects with flunarazine were not statistically significantly more than with placebo. As such, withdrawal could be due to the small sample size in the studies. We have insufficient data to conclude whether nifedipine or nimodipine were more likely to be withdrawn than placebo. The confidence intervals around the estimates were however wide, and there could be substantial withdrawal rates.</P>
<P>We found no adverse effects that were significantly associated with any of the calcium antagonists, which probably represents the small amount of data reviewed. We are, therefore, unable to describe adverse effect profiles for any of the drugs reviewed.</P>
<P>No data were available for quality of life and cognitive effect outcomes for any trials of flunarizine, nimodipine and nifedipine.</P>
<QUALITY_OF_EVIDENCE MODIFIED="2013-02-19 15:11:03 +0000" MODIFIED_BY="[Empty name]">
<P>We used the GRADE approach to assess quality of evidence, and this is presented in <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>; <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>. For the comparison of flunarizine versus placebo, the one study by <LINK REF="STD-Pledger-1994" TYPE="STUDY">Pledger 1994</LINK> for which risk ratios (RRs) were calculated was rated as high in quality of evidence as the study was a well-conducted randomised controlled trial. For the outcome of treatment withdrawal four studies were combined and the evidence was rated as moderate as three of the four studies were at a high risk of bias for outcome reporting. The study which examined nifedipine versus placebo was downgraded to moderate for the inadequate methods used to deal with missing data.</P>
</QUALITY_OF_EVIDENCE>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-02-19 15:47:49 +0000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2013-02-19 14:34:10 +0000" MODIFIED_BY="[Empty name]">
<P>Our results indicate that flunarizine may have a weak effect on seizures, but it had a significant withdrawal rate which probably represents problems with tolerability. Similarly, there is insufficient evidence of effect to recommend the use of nifedipine or nimodipine as antiepileptic drugs. Since only one study was included in the meta-analysis it would be appropriate to conclude that the evidence is inconclusive for the use of these drugs as adjunct therapy for drug-resistant epilepsy.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2013-02-19 15:47:49 +0000" MODIFIED_BY="[Empty name]">
<P>Given that the estimates of effect for the calcium antagonists reviewed were low, and that there are an ever increasing number of antiepileptic drugs for the clinician and patient to choose from, we do not think it is reasonable to undertake further trials with these drugs in people with epilepsy at this time. However, other calcium channel antagonists such as verapamil currently have no data on their use as adjunct therapy for drug-resistant epilepsy. As such it would be appropriate to test them.</P>
<P>Most of the trials reviewed were cross-over trials and some of the problems with this trial design have been highlighted. We would recommend future antiepileptic drug trials to be large parallel-group trials and to examine the effects on patient-centered outcomes such as cognition and quality of life, two important outcomes which were not investigated in any of the included trials.<BR/>
</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2012-04-27 16:04:20 +0100" MODIFIED_BY="[Empty name]">
<P>We acknowledge Drs Rungsan Chaisewikul and Nick Baillie for conducting the previous reviews.<BR/>
</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2013-02-19 14:34:16 +0000" MODIFIED_BY="[Empty name]">
<P>None known</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2012-04-27 16:05:43 +0100" MODIFIED_BY="[Empty name]">
<P>MH and JP were involved in all stages of conducting and writing of the review. Any disagreements were resolved by discussion with Tony Marson who supervised the review and gave comments. </P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2013-02-19 14:35:18 +0000" MODIFIED_BY="[Empty name]">
<P>We included randomised controlled trials which examined differences between two or more active drugs i.e. head to head trials.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2013-02-19 14:55:58 +0000" MODIFIED_BY="Heather Maxwell">
<STUDIES MODIFIED="2013-02-19 14:44:54 +0000" MODIFIED_BY="Heather Maxwell">
<INCLUDED_STUDIES MODIFIED="2012-05-03 16:36:05 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Alving-1989" NAME="Alving 1989" YEAR="1989">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Alving J, Kristensen O, Tsiropoulos I, Mondrup K</AU>
<TI>Double-blind placebo-controlled evaluation of flunarizine as adjunct therapy in epilepsy with complex partial seizures</TI>
<SO>Acta Neurologica Scandinavica</SO>
<YR>1989</YR>
<VL>79</VL>
<PG>128-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Battaglia-1991" NAME="Battaglia 1991" YEAR="1991">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Battaglia A, Ferrari AR, Guerrini R</AU>
<TI>Double-blind placebo-controlled trial of flunarizine as add-on therapy in refractory childhood epilepsy</TI>
<SO>Brain and Development</SO>
<YR>1991</YR>
<VL>13</VL>
<NO>4</NO>
<PG>217-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fr_x00f6_scher-1988" NAME="Fröscher 1988" YEAR="1988">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Froscher W, Bulau P, Burr W, Penin H, Rao ML, de Beukelaar F</AU>
<TI>Double-blind placebo-controlled trial with flunarizine in therapy-resistant epileptic patients</TI>
<SO>Clinical Neuropharmacology</SO>
<YR>1988</YR>
<VL>11</VL>
<NO>3</NO>
<PG>232-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Keene-1989" NAME="Keene 1989" YEAR="1989">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Keene D, Whiting S, Humphreys P, Jacob P</AU>
<TI>Flunarizine as a supplementary medication in refractory childhood epilepsy: a double-blind crossover study</TI>
<SO>Canadian Journal of Neurological Sciences</SO>
<YR>1989</YR>
<VL>16</VL>
<NO>2</NO>
<PG>191-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Larkin-1991" NAME="Larkin 1991" YEAR="1991">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Larkin JG, McKee PJW, Blacklaw J, Thompson GG, Morgan IC, Brodie MJ</AU>
<TI>Nimodipine in refractory epilepsy: a placebo-controlled, add-on study</TI>
<SO>Epilepsy Research</SO>
<YR>1991</YR>
<VL>9</VL>
<PG>71-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Larkin-1992" NAME="Larkin 1992" YEAR="1992">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Larkin JG, Besag FMC, Cox A, Williams J, Brodie MJ</AU>
<TI>Nifedipine for epilepsy? A double-blind, placebo-controlled trial</TI>
<SO>Epilepsia</SO>
<YR>1992</YR>
<VL>33</VL>
<NO>2</NO>
<PG>346-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moglia-1986" NAME="Moglia 1986" YEAR="1986">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Moglia A, Bergamasco B, Di Perri R, Mancia D</AU>
<TI>Flunarizine as add-on therapy in epilepsy: crossover study versus placebo</TI>
<SO>Functional Neurology</SO>
<YR>1986</YR>
<VL>1</VL>
<NO>4</NO>
<PG>547-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Overweg-1984" MODIFIED="2012-05-03 16:36:05 +0100" MODIFIED_BY="[Empty name]" NAME="Overweg 1984" YEAR="1984">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Overweg J, Binnie CD, Meijer JWA, Meinardi H, Nuijten STM, Schmaltz S et al</AU>
<TI>Double-blind placebo-controlled trial of flunarizine as add-on therapy in epilepsy</TI>
<SO>Epilepsia</SO>
<YR>1984</YR>
<VL>25</VL>
<NO>2</NO>
<PG>217-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pelliccia-1993" NAME="Pelliccia 1993" YEAR="1993">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pelliccia A, Sciarretta A, Monticelli M, Porro G, Matricardi M</AU>
<TI>Nimodipine in drug-resistant childhood epilepsy: a double-blind, placebo-controlled trial</TI>
<TO>Impiego della nimodipina nelle epilessia farmacoresistente: studio in doppio cieco placebo-controllato</TO>
<SO>Bolletino Lega Italiana Contro L'Epilessia</SO>
<YR>1993</YR>
<VL>82/83</VL>
<PG>153-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pledger-1994" NAME="Pledger 1994" YEAR="1994">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pledger GW, Sackellares JC, Treiman DM, Pellock JM, Wright FS, Mikati M et al</AU>
<TI>Flunarizine for treatment of partial seizures: results of a concentration-controlled trial</TI>
<SO>Neurology</SO>
<YR>1994</YR>
<VL>44</VL>
<PG>1830-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Starreveld-1989" NAME="Starreveld 1989" YEAR="1989">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Starreveld E, De Beukelaar F, Wilson AF, McLean DR, Findlay HP</AU>
<TI>Double-blind cross-over placebo controlled study of flunarizine in patients with therapy resistant epilepsy</TI>
<SO>Canadian Journal of Neurological Sciences</SO>
<YR>1989</YR>
<VL>16</VL>
<PG>187-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2013-02-19 14:44:54 +0000" MODIFIED_BY="Heather Maxwell">
<STUDY DATA_SOURCE="PUB" ID="STD-Binnie-1985" MODIFIED="2013-02-19 14:41:25 +0000" MODIFIED_BY="[Empty name]" NAME="Binnie 1985" YEAR="1985">
<REFERENCE MODIFIED="2013-02-19 14:41:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Binnie CD, de Beukelaar F, Meijer JW, Meinardi H, Overweg J, Wauquier A, van Wieringen A</AU>
<TI>Open dose-ranging trial of flunarizine as add-on therapy in epilepsy</TI>
<SO>Epilepsia</SO>
<YR>1985</YR>
<VL>26</VL>
<PG>424-8</PG>
<IDENTIFIERS MODIFIED="2012-05-23 10:47:34 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-05-23 10:47:34 +0100" MODIFIED_BY="[Empty name]" OTHERTYPE="ISSN" TYPE="OTHER" VALUE="0013-9580"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-05-23 11:28:49 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cavazzuti-1986" NAME="Cavazzuti 1986" YEAR="1986">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cavazzuti GB, Galli V, Benatti A</AU>
<TI>The use of flunarizine in pediatric epilepsy</TI>
<SO>Functional Neurology</SO>
<YR>1986</YR>
<VL>1</VL>
<NO>4</NO>
<PG>551-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Handforth-1995" MODIFIED="2013-02-19 14:44:34 +0000" MODIFIED_BY="[Empty name]" NAME="Handforth 1995" YEAR="1995">
<REFERENCE MODIFIED="2013-02-19 14:44:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Handforth A, Mai T, Treiman DM
</AU>
<TI>Rising dose study of safety and tolerance of flunarizine</TI>
<SO>European Journal of Clinical Pharmacology</SO>
<YR>1995</YR>
<VL>49</VL>
<PG>91-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Malashkhia-1996" NAME="Malashkhia 1996" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Malashkhia VY, Nadareishvili ZG, Malashkhia YA</AU>
<TI>Add-on therapy with nimodipine in intractable epilepsy of childhood</TI>
<SO>Journal of Child Neurology</SO>
<YR>1996</YR>
<VL>11</VL>
<NO>6</NO>
<PG>500-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meyer-1995" MODIFIED="2011-06-16 15:16:29 +0100" MODIFIED_BY="Heather Maxwell" NAME="Meyer 1995" YEAR="1995">
<REFERENCE MODIFIED="2011-06-16 15:16:29 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cascino GD, Meyer FB, Sharbrough FW, Ivnik RJ, Hirschorn KA, So EL et al</AU>
<TI>Nimodipine for intractable seizures: a double-blind placebo-controlled crossover study</TI>
<SO>Epilepsia</SO>
<YR>1992</YR>
<VL>33 Suppl 3</VL>
<PG>119</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Meyer FB, Cascino GD, Whisnant JP, Sharbrough FW, Ivnik RJ, Gorman DA et al</AU>
<TI>Nimodipine as an add-on therapy for intractable epilepsy</TI>
<SO>Mayo Clinic Proceedings</SO>
<YR>1995</YR>
<VL>70</VL>
<PG>623-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sasso-1993" NAME="Sasso 1993" YEAR="1993">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sasso E, Delsoldato S, Mancia D</AU>
<TI>Nimodipine as adjunctive therapy in refractory epilepsy</TI>
<TO>Effetto della nimodipina nelle epilessie farmacoresistenti</TO>
<SO>Bolletino Lega Italiana Contro L'Epilessia</SO>
<YR>1993</YR>
<VL>82/83</VL>
<PG>155-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Treiman-1993" MODIFIED="2013-02-19 14:44:54 +0000" MODIFIED_BY="[Empty name]" NAME="Treiman 1993" YEAR="1993">
<REFERENCE MODIFIED="2013-02-19 14:44:54 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Treiman DM, Pledger GW, DeGiorgio C, Tsay JY, Cereghino JJ
</AU>
<TI>Increasing plasma concentration tolerability study of flunarizine in comedicated epileptic patients
</TI>
<SO>Epilepsia</SO>
<YR>1993</YR>
<VL>34</VL>
<PG>944-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2013-02-19 14:44:46 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="UNPUB" ID="STD-Andrade-2012" MODIFIED="2013-02-19 14:44:46 +0000" MODIFIED_BY="[Empty name]" NAME="Andrade 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-02-19 14:44:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<TI>Verapamil study in refractory epilepsy</TI>
<SO>http://clinicaltrials.gov/ct2/show/NCT01126307</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-05-25 11:31:26 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-05-25 11:31:26 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE=" NCT01126307"/>
</IDENTIFIERS>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-02-19 14:55:58 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2013-02-19 14:55:58 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Bonnett-2012" MODIFIED="2013-02-19 14:46:55 +0000" MODIFIED_BY="[Empty name]" NAME="Bonnett 2012" TYPE="JOURNAL_ARTICLE">
<AU>Bonnett L, Smith CT, Smith D, Williamson P, Chadwick D, Marson AG</AU>
<TI>Prognostic factors for time to treatment failure and time to 12 months of remission for patients with focal epilepsy: post-hoc, subgroup analyses of data from the SANAD trial</TI>
<SO>Lancet Neurology</SO>
<YR>2012</YR>
<VL>11</VL>
<NO>4</NO>
<PG>331-40</PG>
<IDENTIFIERS MODIFIED="2012-06-17 16:58:43 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-06-17 16:58:43 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1016/S1474-4422(12)70018-2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2010" MODIFIED="2012-06-18 08:55:57 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2010" TYPE="BOOK">
<AU>Higgins J, Green S</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions</SO>
<YR>2010</YR>
<PB>John Wiley &amp; Sons Ltd</PB>
<CY>West Sussex</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jouvenceau-2001" MODIFIED="2013-02-19 14:54:21 +0000" MODIFIED_BY="[Empty name]" NAME="Jouvenceau 2001" TYPE="JOURNAL_ARTICLE">
<AU>Jouvenceau A, Eunson LH, Spauschus A, Ramesh V, Zuberi SM, Kullmann DM et al</AU>
<TI>Human epilepsy associated with dysfunction of the brain P/Q-type calcium channel</TI>
<SO>Lancet</SO>
<YR>2001</YR>
<VL>358</VL>
<NO>9284</NO>
<PG>801-7</PG>
<IDENTIFIERS MODIFIED="2012-04-26 21:48:32 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-04-26 21:48:32 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1016/S0140-6736(01)05971-2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Nunes-2012" MODIFIED="2013-02-19 14:54:08 +0000" MODIFIED_BY="[Empty name]" NAME="Nunes 2012" TYPE="JOURNAL_ARTICLE">
<AU>Nunes VD, Sawyer L, Neilson J, Sarri G, Cross JH</AU>
<TI>Diagnosis and management of the epilepsies in adults and children: summary of updated NICE guidance</TI>
<SO>BMJ</SO>
<YR>2012</YR>
<VL>344</VL>
<PG>e281</PG>
<IDENTIFIERS MODIFIED="2012-04-26 22:01:42 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Reynolds-1993" MODIFIED="2012-06-01 12:58:06 +0100" MODIFIED_BY="[Empty name]" NAME="Reynolds 1993" TYPE="BOOK">
<AU>Reynolds J</AU>
<SO>Martindale: The extra pharmacopoeia</SO>
<YR>1993</YR>
<EN>30th</EN>
<PB>Pharmaceutical Press</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Smith-2005" MODIFIED="2013-02-19 14:54:58 +0000" MODIFIED_BY="[Empty name]" NAME="Smith 2005" TYPE="JOURNAL_ARTICLE">
<AU>Smith SJM</AU>
<TI>EEG in the diagnosis, classification, and management of patients with epilepsy</TI>
<SO>Journal of Neurology, Neurosurgery, and Psychiatry</SO>
<YR>2005</YR>
<VL>76</VL>
<PG>ii2-ii7</PG>
<IDENTIFIERS MODIFIED="2012-04-26 21:50:00 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-04-26 21:50:00 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1136/jnnp.2005.069245"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Summers-2004" MODIFIED="2013-02-19 14:55:47 +0000" MODIFIED_BY="[Empty name]" NAME="Summers 2004" TYPE="JOURNAL_ARTICLE">
<AU>Summers MA, Moore JL, McAuley JW</AU>
<TI>Use of verapamil as a potential P-glycoprotein inhibitor in a patient with refractory epilepsy</TI>
<SO>The Annals of Pharmacotherapy</SO>
<YR>2004</YR>
<VL>38</VL>
<NO>10</NO>
<PG>1631-4</PG>
<IDENTIFIERS MODIFIED="2012-04-26 22:08:19 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-04-26 22:08:19 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1345/aph.1E068"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Triggle-2007" MODIFIED="2013-02-19 14:55:58 +0000" MODIFIED_BY="[Empty name]" NAME="Triggle 2007" TYPE="JOURNAL_ARTICLE">
<AU>Triggle DJ</AU>
<TI>Calcium channel antagonists: Clinical uses - past, present and future</TI>
<SO>Biochemical Pharmacology</SO>
<YR>2007</YR>
<VL>74</VL>
<NO>1</NO>
<PG>1-9</PG>
<IDENTIFIERS MODIFIED="2012-04-26 22:05:31 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-04-26 22:05:31 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1016/j.bcp.2007.01.016"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2013-01-09 03:23:01 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Chaisewikul-2001" MODIFIED="2013-01-09 03:23:01 +0000" MODIFIED_BY="[Empty name]" NAME="Chaisewikul 2001" TYPE="COCHRANE_REVIEW">
<AU>Chaisewikul R, Baillie N, Marson AG</AU>
<TI>Calcium antagonists as an add-on therapy for drug-resistant epilepsy</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2013-01-09 03:23:01 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-01-09 03:23:01 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002750"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-02-19 15:39:21 +0000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2013-02-19 15:39:21 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2013-02-19 15:11:57 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Alving-1989">
<CHAR_METHODS MODIFIED="2013-02-19 15:11:57 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised double-blind placebo-controlled cross-over trial.<BR/>2 treatment sequences: placebo-flunarizine and flunarizine-placebo sequences.<BR/>Baseline = 4 weeks.<BR/>No titration period.<BR/>Treatment phase 1 and 2 = 16 weeks each.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-01 12:16:40 +0100" MODIFIED_BY="[Empty name]">
<P>Single Danish centre.<BR/>Total randomised 29; all with drug-resistant partial epilepsy; numbers of randomised patients into individual treatment sequence groups = data not available.<BR/>41% male.<BR/>Age range 14 to 58 years.<BR/>Other AEDs = 1 to 3.<BR/>Baseline seizure frequency: data not available.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-21 14:18:14 +0100" MODIFIED_BY="[Empty name]">
<P>Flunarizine 15 mg per day.</P>
<P>Placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-19 14:35:28 +0000" MODIFIED_BY="[Empty name]">
<P>The following outcomes were measured:</P>
<P>1) Seizure incidence during flunarizine and placebo periods were measured.</P>
<P>2) 50% or greater reduction in seizure frequency.</P>
<P>3) Treatment withdrawal.</P>
<P>4) Side effects.</P>
<P>5) Neuropsychological changes.</P>
<P>6) Treatment preference.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-01-09 03:15:05 +0000" MODIFIED_BY="[Empty name]">
<P>We were not able to acquire the data from the first treatment phase for meta-analysis for any outcomes.</P>
<P>Study was funded by Janssenpharma A/S.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-19 15:39:10 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Battaglia-1991">
<CHAR_METHODS MODIFIED="2013-02-19 15:39:10 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised double-blind placebo-controlled cross-over trial.<BR/>2 treatment sequences: placebo-flunarizine and flunarizine-placebo sequences.<BR/>Baseline = 16 weeks.<BR/>No titration period.<BR/>Treatment phase 1 and 2 = 16 weeks each.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-19 15:31:44 +0000" MODIFIED_BY="[Empty name]">
<P>Single Italian centre.<BR/>Total fed 20; all with drug-resistant partial or generalized epilepsy; numbers of randomised patients into individual treatment sequence groups = data not available.<BR/>50% male.<BR/>Age range = 6 to 18 years (mean 12 years 7 months).<BR/>Other AEDs: most patients on 2 to 3.<BR/>Baseline seizure frequency: data not available.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-19 14:36:18 +0000" MODIFIED_BY="Heather Maxwell">
<P>1) Flunarizine 5 mg/d for age &lt; 10 years or 10 mg/d for age &gt; 10 years.</P>
<P>2) Placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-19 14:36:20 +0000" MODIFIED_BY="[Empty name]">
<P>The following outcomes were measured:</P>
<P>1) Seizure incidence during flunarizine and placebo periods.</P>
<P>2) 30%, 40% and 60% greater reduction in seizure frequency.</P>
<P>3) Treatment withdrawal.</P>
<P>4) Adverse effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-01 11:24:53 +0100" MODIFIED_BY="[Empty name]">
<P>We were not able to acquire the data from the first treatment phase for meta-analysis for any outcomes.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-19 15:39:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fr_x00f6_scher-1988">
<CHAR_METHODS MODIFIED="2013-02-19 15:39:21 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised double-blind placebo-controlled cross-over trial.<BR/>2 treatment sequences: placebo-flunarizine and flunarizine-placebo sequences.<BR/>Baseline = 8 weeks.<BR/>Titration period = 3 weeks.<BR/>Treatment phase 1 and 2 = 16 weeks each.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-01 12:16:47 +0100" MODIFIED_BY="[Empty name]">
<P>Single Belgian centre.<BR/>Total randomised 30; all with drug-resistant partial epilepsy. 14 to placebo-flunarizine sequence; 16 to flunarizine-placebo sequence.<BR/>57% male.<BR/>Age range 14 to 51 years.<BR/>Other AEDs: most patients on 1 to 3.<BR/>Baseline seizure frequency: data not available.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-19 14:36:31 +0000" MODIFIED_BY="[Empty name]">
<P>1) Flunarizine 15 mg/day</P>
<P>2) Placebo pill.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-19 14:36:35 +0000" MODIFIED_BY="[Empty name]">
<P>Following outcomes were reported:</P>
<P>1) Seizure incidence during flunarizine and placebo periods.</P>
<P>2) Change (%) of seizure frequency compared between the last month of each treatment phase.</P>
<P>3) Effect on severity and duration of seizures.</P>
<P>4) Treatment withdrawal.</P>
<P>5) Adverse effects.</P>
<P>6) Flunarizine plasma concentration.</P>
<P>7) Interaction with existing AEDs (total and free blood levels).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-07-05 16:04:36 +0100" MODIFIED_BY="[Empty name]">
<P>The first author was not able to provide data for the treatment allocation method and its concealment as well as data for the following outcomes from the first treatment phase due to those data no longer being available: (a) 50% or greater reduction in seizure frequency; (b) side effects.</P>
<P>We used the data of treatment withdrawal from the first treatment phase for meta-analysis.</P>
<P>We presented the data of 50% responders and side effects from both treatment phases in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> and <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK> respectively.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-19 15:32:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Keene-1989">
<CHAR_METHODS MODIFIED="2013-02-19 15:32:58 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised double-blind placebo-controlled cross-over trial.<BR/>2 treatment sequences: placebo-flunarizine and flunarizine-placebo sequences.<BR/>Baseline = 4 weeks.<BR/>No titration period.<BR/>Treatment phase 1 and 2 = 12 weeks each.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-19 14:36:52 +0000" MODIFIED_BY="[Empty name]">
<P>Single Canadian centre.<BR/>Total randomised 34; all with drug-resistant partial and generalized epilepsy; 16 to placebo-flunarizine sequence; 18 to flunarizine-placebo sequence.<BR/>56% male.<BR/>Age range 2 to 18 years (mean 15.5 years).<BR/>Other AEDs: data not available.<BR/>Baseline seizure frequency: data not available.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-19 14:36:54 +0000" MODIFIED_BY="[Empty name]">
<P>1) Flunarizine:<BR/>(a) 5 mg/d for BW less than 20 kg;<BR/>(b) 10 mg/d for BW 20 to 40 kg;<BR/>(c) 15 mg/d for BW more than 40 kg.</P>
<P>2) Placebo pill</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-19 14:36:57 +0000" MODIFIED_BY="[Empty name]">
<P>Following outcomes were measured:</P>
<P>1) 50% or greater reduction in seizure frequency.</P>
<P>2) Treatment withdrawal.</P>
<P>3) Adverse effects.</P>
<P>4) Serum flunarizine level.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-07-05 16:04:36 +0100" MODIFIED_BY="[Empty name]">
<P>The first author was not able to provide data for the treatment allocation method and data for the following outcomes from the first treatment phase:<BR/>(a) 50% or greater reduction in seizure frequency;<BR/>(b) adverse effects.</P>
<P>We used the data of treatment withdrawal from the first treatment phase for meta-analysis.</P>
<P>We presented the data of 50% responders and adverse effects from both treatment phases in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> and <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK> respectively.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-19 15:33:15 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Larkin-1991">
<CHAR_METHODS MODIFIED="2013-02-19 15:33:15 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised double-blind placebo-controlled cross-over trial.<BR/>2 treatment sequences: placebo-nimodipine and nimodipine-placebo sequences.<BR/>Baseline = 4 weeks.<BR/>No titration period.<BR/>Treatment phase 1 and 2 = 12 weeks each.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-19 14:37:22 +0000" MODIFIED_BY="[Empty name]">
<P>Single British centre.<BR/>Total randomised 22; all with drug-resistant partial and generalized epilepsy; numbers of randomised participants into individual treatment sequence groups = data not available.<BR/>36% male.<BR/>Age range 18 to 53 years.<BR/>Other AEDs = 1 to 2.<BR/>Baseline seizure frequency: data not available.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-19 14:37:31 +0000" MODIFIED_BY="[Empty name]">
<P>1) Nimodipine:<BR/>(a) 90 mg/d for the initial 4 weeks;<BR/>(b) 180 mg/d for the middle 4 weeks;<BR/>(c) 270 mg/d for the final 4 weeks.</P>
<P>2) Placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-19 14:37:36 +0000" MODIFIED_BY="[Empty name]">
<P>Outcomes reported:</P>
<P>1) 25% and 50% or greater reduction in generalized tonic-clonic or partial seizures or seizure days.</P>
<P>2) Treatment withdrawal.</P>
<P>3) Adverse effects.</P>
<P>4) Heart rate and systolic blood pressure.</P>
<P>5) Drug preference.</P>
<P>6) Serum concentration of nimodipine and concomitant AEDs.</P>
<P>7) Correlations between nimodipine concentrations and changes in seizure control.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-02-19 14:37:41 +0000" MODIFIED_BY="[Empty name]">
<P>The last author was not able to provide data for the randomisation method, allocation concealment and blinding method as well as data for any outcomes from the first treatment phase because those data are no longer available.</P>
<P>Study was funded by Bayer U.K.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-19 14:38:03 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Larkin-1992">
<CHAR_METHODS MODIFIED="2013-02-19 14:37:54 +0000" MODIFIED_BY="[Empty name]">
<P>Balanced double-blind placebo-controlled cross-over trial.<BR/>2 treatment sequences: placebo-nifedipine and nifedipine-placebo sequences.<BR/>Baseline = 8 weeks.<BR/>No titration period.<BR/>Treatment phase 1 and 2 = 8 weeks each.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-01 12:16:56 +0100" MODIFIED_BY="[Empty name]">
<P>Single British centre.<BR/>Total randomised 22; all with drug-resistant partial and generalized epilepsy; 12 to placebo-nifedipine sequence; 10 to nifedipine-placebo sequence.<BR/>55% male.<BR/>Age range 17 to 22 years.<BR/>Other AEDs = 1 to 4.<BR/>Baseline seizure frequency: data not available.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-19 14:37:56 +0000" MODIFIED_BY="[Empty name]">
<P>1) Nifedipine 40 mg/d during the initial half period then 80 mg/d during the final half period.</P>
<P>2) Placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-19 14:38:03 +0000" MODIFIED_BY="[Empty name]">
<P>Following outcomes reported:</P>
<P>1) Total number of any seizures in each treatment phase.</P>
<P>2) Total number of partial seizures in each treatment phase.</P>
<P>3) 50% or greater reduction in seizure frequency.</P>
<P>4) Treatment withdrawal.</P>
<P>5) Adverse events.</P>
<P>6) Heart rate and blood pressure.</P>
<P>7) Serum nifedipine concentrations 1 hour post dosing at 4 weeks on 20 mg twice daily and at 4 weeks on 40 mg twice daily.</P>
<P>8) Correlation between improvement in total seizure numbers, in partial seizure numbers, and nifedipine concentration following 8 weeks of treatment.</P>
<P>9) Comparison of total electroencephalography scores with nifedipine and placebo.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-01 11:41:05 +0100" MODIFIED_BY="[Empty name]">
<P>The last author was not able to provide data for the treatment allocation method and its concealment as well as data for the following outcomes from the first treatment phase because those data are no longer available:<BR/>(a) 50% or greater reduction in seizure frequency;<BR/>(b) adverse effects.</P>
<P>We used the data of treatment withdrawal from the first treatment phase for analysis.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-19 14:38:35 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Moglia-1986">
<CHAR_METHODS MODIFIED="2013-02-19 14:38:26 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised double-blind placebo-controlled cross-over trial.<BR/>2 treatment sequences: placebo-flunarizine and flunarizine-placebo sequences.<BR/>Baseline = 12 weeks.<BR/>No titration period.<BR/>Treatment phase 1 and 2 = 12 weeks each.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-19 14:38:29 +0000" MODIFIED_BY="[Empty name]">
<P>Single Italian centre.<BR/>Total randomised 90; all with drug-resistant partial and generalized epilepsy; 42 to placebo-flunarizine sequence; 48 to flunarizine-placebo sequence.<BR/>57% male.<BR/>Age range 15 to 73 years.<BR/>Other AEDs: data not available.<BR/>Baseline seizure frequency: data not available.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-19 14:38:33 +0000" MODIFIED_BY="[Empty name]">
<P>1) Flunarizine:<BR/>(a) 10 mg/d for BW less than 70 kg;<BR/>(b) 15 mg/d for BW more than70 kg.</P>
<P>2) Placebo pill.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-19 14:38:35 +0000" MODIFIED_BY="[Empty name]">
<P>Outcomes Reported:</P>
<P>1) Incidence of seizure per month before and at the end of each treatment.</P>
<P>2) 50% or greater reduction in seizure frequency.</P>
<P>3) Treatment withdrawal.</P>
<P>4) Adverse effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-01 11:42:22 +0100" MODIFIED_BY="[Empty name]">
<P>The first author was not able to provide data for the treatment allocation method and its concealment as well as data for the following outcomes from the first treatment phase because those data are no longer available:<BR/>(a) 50% or greater reduction in seizure frequency;<BR/>(b) adverse effects.</P>
<P>We used the data of treatment withdrawal from the first treatment phase for meta-analysis.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-19 15:33:55 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Overweg-1984">
<CHAR_METHODS MODIFIED="2013-02-19 15:33:50 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised double-blind placebo-controlled cross-over trial.<BR/>2 treatment sequences: placebo-flunarizine and flunarizine-placebo sequences.<BR/>Baseline = 12 weeks.<BR/>No titration period.<BR/>Treatment phase 1 and 2 = 12 weeks each.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-19 15:33:55 +0000" MODIFIED_BY="[Empty name]">
<P>Single Dutch centre.<BR/>Total randomised 33; all with drug-resistant partial and generalized epilepsy; numbers of randomised participants to individual treatment sequence groups not available.<BR/>55% male.<BR/>All adults.<BR/>Other AEDs: most patients on 1 to 3.<BR/>Baseline seizure frequency: data not available.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-19 14:38:53 +0000" MODIFIED_BY="[Empty name]">
<P>1) Flunarizine 10 mg per day.</P>
<P>2) Placebo pill.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-19 14:38:54 +0000" MODIFIED_BY="[Empty name]">
<P>Following outcomes reported:</P>
<P>1) Total seizure incidence during on each treatment.</P>
<P>2) 25% or more and 50% or greater reduction in seizure frequency.</P>
<P>3) Treatment withdrawal.</P>
<P>4) Adverse effects.</P>
<P>5) Blood level of concomitant AEDs.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-01 11:48:38 +0100" MODIFIED_BY="[Empty name]">
<P>We were not able to acquire the data from the first treatment phase for meta-analysis for any outcomes.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-19 15:34:10 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pelliccia-1993">
<CHAR_METHODS MODIFIED="2013-02-19 15:34:10 +0000" MODIFIED_BY="[Empty name]">
<P>Quasi-randomised, double-blind, placebo-controlled, cross-over trial.<BR/>2 treatment sequences: placebo-nimodipine and nimodipine-placebo sequences.<BR/>Baseline = 30 days.<BR/>No titration period.<BR/>Treatment phase 1 and 2 = 12 weeks each.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-19 14:39:05 +0000" MODIFIED_BY="[Empty name]">
<P>Single Italian centre.<BR/>Total randomised 17; 8 randomised into nimodipine-placebo sequence and 9 randomised into placebo-nimodipine sequence.<BR/>All with drug-resistant partial and generalized epilepsy.<BR/>53% male.<BR/>Age range 5 to 22 years.<BR/>Other AEDs: 1 to 3.<BR/>Baseline seizure frequency: range 3 to 603 per month, mean 166.7 per month.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-19 14:39:10 +0000" MODIFIED_BY="[Empty name]">
<P>1) Nimodipine 1.5 to 2 mg/kg/d.</P>
<P>2) Placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-19 14:39:13 +0000" MODIFIED_BY="[Empty name]">
<P>Following outcomes reported:</P>
<P>1) Incidence of total, partial, generalized, absence seizures or seizure days.</P>
<P>2) 25% or more and 50% or greater reduction in seizure frequency.</P>
<P>3) Treatment withdrawal.</P>
<P>4) Adverse effects.</P>
<P>5) Blood level of concomitant AEDs.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>We used the data from the first treatment phase for analysis for the outcomes of 50% or greater reduction in seizure frequency, treatment withdrawal and adverse effects.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-19 14:39:48 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pledger-1994">
<CHAR_METHODS MODIFIED="2013-02-19 14:39:30 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised double-blind placebo-controlled parallel trial.<BR/>2 treatment arms: 1 placebo and 1 flunarizine.<BR/>Baseline = 12 weeks.<BR/>Titration period = 1 week.<BR/>Treatment phase = 24 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-19 14:39:43 +0000" MODIFIED_BY="[Empty name]">
<P>All adults. Multicentre across USA.<BR/>Total randomised 93; all with drug-resistant partial epilepsy; 47 to placebo; 46 to flunarizine.<BR/>47% male.<BR/>Age range 16 to 64 years.<BR/>Other AEDs: 1 to 2.<BR/>Baseline seizure frequency per week: mean = 6, median = 3.5, range = 1 to 31.8.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-19 14:39:45 +0000" MODIFIED_BY="[Empty name]">
<P>1) Adjusted dose of flunarizine to keep plasma concentration at 60 ng/ml.</P>
<P>2) Placebo pills.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-19 14:39:48 +0000" MODIFIED_BY="[Empty name]">
<P>Following outcomes reported:</P>
<P>1) Seizures, seizure duration and seizure severity per cent reduction.</P>
<P>2) 50% or greater reduction in seizure frequency.</P>
<P>3) Treatment withdrawal.</P>
<P>4) Adverse effects.</P>
<P>5) Plasma concentrations of flunarizine and concomitant AEDs.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>We used the data of 50% or greater reduction in seizure frequency and adverse effects for analyses. <BR/>We also used the data of treatment withdrawal for meta-analysis.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-19 14:40:09 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Starreveld-1989">
<CHAR_METHODS MODIFIED="2013-02-19 14:39:59 +0000" MODIFIED_BY="[Empty name]">
<P>Double-blind placebo-controlled cross-over trial.<BR/>Baseline = 8 weeks.<BR/>No titration period.<BR/>Treatment phase 1 and 2 = 16 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-19 14:40:02 +0000" MODIFIED_BY="[Empty name]">
<P>Single Canadian centre.<BR/>Total randomised 34; all with drug-resistant partial epilepsy; numbers of randomised participants into individual treatment sequence groups not available.<BR/>38% male.<BR/>Age range within 15 to 60 years.<BR/>Other AEDs: most participants on 1 to 2.<BR/>Baseline seizure frequency: data not available.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-19 14:40:04 +0000" MODIFIED_BY="[Empty name]">
<P>1) Flunarizine 15 mg per day.</P>
<P>2) Placebo.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-19 14:40:09 +0000" MODIFIED_BY="[Empty name]">
<P>Following outcomes were reported:</P>
<P>1) Total seizure frequency on each treatment phase.</P>
<P>2) 25%, 25 to 49%, and 50% or greater reduction in seizure frequency.</P>
<P>3) Treatment withdrawal.</P>
<P>4) Adverse effects.</P>
<P>5) Serum concentration of flunarizine and concomitant AEDs.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-01 11:45:52 +0100" MODIFIED_BY="[Empty name]">
<P>We were not able to acquire the data from the first treatment phase for meta-analyses for any of the outcomes.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>AED: antiepileptic drug<BR/>BW: body weight</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2013-02-19 14:40:24 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2013-02-19 14:40:18 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Binnie-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-19 14:40:18 +0000" MODIFIED_BY="[Empty name]">
<P>Not RCT due to lack of randomisation. Three patient arms from a previous study were entered into this study as one arm. Placebo was not mentioned in the methods.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cavazzuti-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Some participants received study medication for less than 8 weeks.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-01 08:56:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Handforth-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-01 08:56:08 +0100" MODIFIED_BY="[Empty name]">
<P>The paper reports results from a previous RCT and then presents the results of an open-label extension study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-19 14:40:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Malashkhia-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-19 14:40:24 +0000" MODIFIED_BY="[Empty name]">
<P>Although this study was a randomised trial, it was not a placebo-controlled trial and all concurrent AEDs were substituted with phenobarbitone rather than being kept unchanged.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Meyer-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>This trial did not investigate for 50% or greater reduction in seizure frequency. We were also unable to acquire the proportion of participants having treatment withdrawn and the proportion of participants experiencing individual adverse effects in individual treatment groups in the first treatment phase.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sasso-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>This trial did not investigate for 50% or greater reduction in seizure frequency. We were also unable to acquire the proportion of participants having treatment withdrawn and the proportion of participants experiencing individual adverse effects in individual treatment groups.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-05-30 09:02:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Treiman-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-05-30 09:02:17 +0100" MODIFIED_BY="[Empty name]">
<P>Pilot study to assess concentration treatment for 34 days. Not RCT, concentration-controlled study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>AED: antiepileptic drug</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2013-02-19 14:40:42 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2013-02-19 14:40:42 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Andrade-2012">
<CHAR_METHODS MODIFIED="2013-02-19 14:40:35 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised double-blind interventional controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-25 11:34:16 +0100" MODIFIED_BY="[Empty name]">
<P>18 to 60 year old patients with refractory epilepsy. Both genders included. </P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-19 14:40:37 +0000" MODIFIED_BY="[Empty name]">
<P>Drug: Verapamil (80 mg TID).</P>
<P>Drug: Placebo (TID).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-19 14:40:42 +0000" MODIFIED_BY="[Empty name]">
<P>Primary outcome measures:</P>
<UL>
<LI>percentage reduction of seizure frequency (time frame: 3 months) (designated as safety issue: No) after 3 months of treatment compared to baseline.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-02-19 14:40:42 +0000" MODIFIED_BY="[Empty name]">
<P>Taking place in Toronto.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2013-02-19 15:39:15 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2013-02-19 15:34:20 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 15:12:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Alving-1989">
<DESCRIPTION>
<P>Quote - "randomised"</P>
<P>Comment - No details of method of randomisation therefore uncertain risk of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 15:32:26 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Battaglia-1991">
<DESCRIPTION>
<P>Quote - "randomised"</P>
<P>Comment - No details of method of randomisation therefore uncertain risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 15:32:46 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fr_x00f6_scher-1988">
<DESCRIPTION>
<P>Quote - "randomised"</P>
<P>Comment - No details of method of randomisation therefore uncertain risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 15:33:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Keene-1989">
<DESCRIPTION>
<P>Quote - "randomised"</P>
<P>Comment - No details of method of randomisation therefore uncertain risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 15:33:24 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Larkin-1991">
<DESCRIPTION>
<P>Quote - "randomised"</P>
<P>Comment - No details of method of randomisation therefore uncertain risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 15:33:34 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Larkin-1992">
<DESCRIPTION>
<P>Quote - "randomised"</P>
<P>Comment - No details of method of randomisation therefore uncertain risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 15:33:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moglia-1986">
<DESCRIPTION>
<P>Quote - "Patients divided into two equal groups"</P>
<P>Comment - The study is listed as a randomised trial but there is no evidence in the paragraphs of the study, only this vague sentence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 15:34:01 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Overweg-1984">
<DESCRIPTION>
<P>Quote - "randomised"</P>
<P>Comment - No details of method of randomisation therefore uncertain risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 15:34:15 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Pelliccia-1993">
<DESCRIPTION>
<P>Comment - Random list generation: order of entry into trial, allocation by odd or even numbers</P>
<P>No true &#8220;Randomisation&#8221;. There is a pattern to the selection</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 14:39:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pledger-1994">
<DESCRIPTION>
<P>Comment - Authors noted that the random sequence was stratified by a computer</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 15:34:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Starreveld-1989">
<DESCRIPTION>
<P>Quote - "randomised"</P>
<P>Comment - No details of method of randomisation therefore uncertain risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2013-02-19 15:39:15 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 14:35:35 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Alving-1989">
<DESCRIPTION>
<P>Comment - No details of allocation concealment therefore uncertain risk of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 15:39:15 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Battaglia-1991">
<DESCRIPTION>
<P>Quote - "randomised"</P>
<P>Comment - No details of method of allocation concealment therefore uncertain risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 15:32:53 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fr_x00f6_scher-1988">
<DESCRIPTION>
<P>Quote - "randomised"</P>
<P>Comment - No details of method of allocation concealment therefore uncertain risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 15:33:09 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Keene-1989">
<DESCRIPTION>
<P>Quote - "randomised"</P>
<P>Comment - No explicit details provided in the study but authors contacted and said sealed envelopes were given to subjects</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 15:33:29 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Larkin-1991">
<DESCRIPTION>
<P>Quote - "randomised"</P>
<P>Comment - No details of method of allocation concealment therefore uncertain risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 15:33:39 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Larkin-1992">
<DESCRIPTION>
<P>Quote - "randomised"</P>
<P>Comment - No details of method of allocation concealment therefore uncertain risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 14:38:40 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moglia-1986">
<DESCRIPTION>
<P>Comment - Unclear, no data available on concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 15:34:06 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Overweg-1984">
<DESCRIPTION>
<P>Quote - "randomised"</P>
<P>Comment - No details of method of allocation concealment therefore uncertain risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 14:39:16 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pelliccia-1993">
<DESCRIPTION>
<P>Quote - "sequential sealed packages."</P>
<P>Comment - adequate method of concealment chosen</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 14:39:51 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pledger-1994">
<DESCRIPTION>
<P>Quote "treatment allocated by the centre and kept at pharmacy separated from study site."</P>
<P>Comment - Appropriate treatment allocation sequence by authors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 15:34:25 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Starreveld-1989">
<DESCRIPTION>
<P>Quote - "randomised"</P>
<P>Comment - No details of method of allocation concealment therefore uncertain risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2013-02-19 14:40:10 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>Seizure Reduction</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-02-18 08:28:41 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Alving-1989">
<DESCRIPTION>
<P>Quote - "Double Blinded"</P>
<P>Comment - No details given to how blinding was achieved</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-02-19 14:36:27 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Battaglia-1991">
<DESCRIPTION>
<P>Quote - "Blinded"</P>
<P>Comment - No details of method of blinding therefore uncertain risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-02-19 14:36:41 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fr_x00f6_scher-1988">
<DESCRIPTION>
<P>Quote - "Blinded"</P>
<P>Comment - No details of method of blinding therefore uncertain risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-02-19 14:37:05 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Keene-1989">
<DESCRIPTION>
<P>Quote - "Identical appearance for flunarazine and placebo pills"</P>
<P>Comment - Key study personnel were not aware which pills were active and which were placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-02-19 14:37:49 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Larkin-1991">
<DESCRIPTION>
<P>Quote - "Identical appearance for Nimodipine and placebo pills"</P>
<P>Comment - Key study personnel were not aware which pills were active and which were placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-02-19 14:38:07 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Larkin-1992">
<DESCRIPTION>
<P>Quote - "Identical appearance for Nifdepine and placebo pills"</P>
<P>Comment- Did not mention if Key study personnel were aware which pills were active and which were placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-02-19 14:38:42 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moglia-1986">
<DESCRIPTION>
<P>Comment - No data regarding blinding was provided. The word itself is not mentioned in the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-02-19 14:38:56 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Overweg-1984">
<DESCRIPTION>
<P>Quote - "Blinded"</P>
<P>Comment - No details of method of blinding therefore uncertain risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-06-01 11:45:06 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Pelliccia-1993">
<DESCRIPTION>
<P>Quote - "allocation by odd or even numbers."</P>
<P>Comment - Key study personnel would be able to memorize if the patient is on an active or placebo pill if they knew what their order was (odd or even)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-02-19 14:39:52 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pledger-1994">
<DESCRIPTION>
<P>Comment - All personnel involved in the study were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-02-19 14:40:10 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Starreveld-1989">
<DESCRIPTION>
<P>Quote - "Blinded"</P>
<P>Comment - No details of method of blinding therefore uncertain risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2013-02-19 14:40:11 +0000" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>Seizure Reduction</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-06-01 11:19:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alving-1989">
<DESCRIPTION>
<P>Quote - "Flunarazine pills and placebo were identical"</P>
<P>Comment - Participants were adequately blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-19 14:36:27 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Battaglia-1991">
<DESCRIPTION>
<P>Quote - "Blinded"</P>
<P>Comment - No details of method of blinding therefore uncertain risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-19 14:36:42 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fr_x00f6_scher-1988">
<DESCRIPTION>
<P>Quote - "Blinded"</P>
<P>Comment - No details of method of blinding therefore uncertain risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-19 14:37:05 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Keene-1989">
<DESCRIPTION>
<P>Quote - "Identical appearance for flunarazine and placebo pills"</P>
<P>Comment - Participants were not aware which pills were active and which were placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-19 14:37:49 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Larkin-1991">
<DESCRIPTION>
<P>Quote "Identical appearance for Nimodipine and placebo pills"</P>
<P>Comment - Participants were not aware which pills were active and which were placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-19 14:38:10 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Larkin-1992">
<DESCRIPTION>
<P>Quote - "Identical appearance for Nifdepine and placebo pills"</P>
<P>Comment - Patients were not aware which pills were active and which were placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-19 14:38:42 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moglia-1986">
<DESCRIPTION>
<P>Comment - No data regarding blinding was provided. The word itself is not mentioned in the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-19 14:38:57 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Overweg-1984">
<DESCRIPTION>
<P>Quote - "Blinded"</P>
<P>Comment - No details of method of blinding therefore uncertain risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-19 14:39:18 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pelliccia-1993">
<DESCRIPTION>
<P>Quote - "Identical appearance for nimodipine and placebo"</P>
<P>Comment - Subjects unaware of the medication they were taking</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-19 14:39:52 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pledger-1994">
<DESCRIPTION>
<P>Comment - All personnel involved in the study were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-19 14:40:11 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Starreveld-1989">
<DESCRIPTION>
<P>Quote - "Blinded"</P>
<P>Comment - No details of method of blinding therefore uncertain risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2013-02-19 14:40:12 +0000" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>Seizure Reduction</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-01 11:19:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Alving-1989">
<DESCRIPTION>
<P>Quote - "Double Blinded"</P>
<P>Comment - No details given to how blinding was achieved</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-19 14:36:28 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Battaglia-1991">
<DESCRIPTION>
<P>Quote - "Blinded"</P>
<P>Comment - No details of method of blinding therefore uncertain risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-19 14:36:43 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fr_x00f6_scher-1988">
<DESCRIPTION>
<P>Quote - "Blinded"</P>
<P>Comment - No details of method of blinding therefore uncertain risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-19 14:37:06 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Keene-1989">
<DESCRIPTION>
<P>Comment - No details on outcome assessors provided and how they were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-19 14:37:50 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Larkin-1991">
<DESCRIPTION>
<P>Comment - No details on outcome assessors provided and how they were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-19 14:38:11 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Larkin-1992">
<DESCRIPTION>
<P>Comment - No details given on how assessors were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-19 14:38:43 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moglia-1986">
<DESCRIPTION>
<P>Comment - No data regarding blinding was provided. The word itself is not mentioned in the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-19 14:38:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Overweg-1984">
<DESCRIPTION>
<P>Quote - "Blinded"</P>
<P>Comment - No details of method of blinding therefore uncertain risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-19 14:39:19 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pelliccia-1993">
<DESCRIPTION>
<P>Comment - No information given on how outcome assessors were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-19 14:39:53 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pledger-1994">
<DESCRIPTION>
<P>Comment - All personnel involved in the study were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-19 14:40:12 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Starreveld-1989">
<DESCRIPTION>
<P>Quote - "Blinded"</P>
<P>Comment - No details of method of blinding therefore uncertain risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2013-02-19 14:40:13 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>Seizure Reduction</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-19 14:36:06 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Alving-1989">
<DESCRIPTION>
<P>Comment - Missing data and study attrition reported but no intention-to-treat analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-19 14:36:28 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Battaglia-1991">
<DESCRIPTION>
<P>Comment - Missing data reported but no intention to treat analysis performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-19 14:36:44 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fr_x00f6_scher-1988">
<DESCRIPTION>
<P>Comment - The study has two phases and seizure reduction was not provided for the first phase and the authors commented that the data was lost as such it is not possible to discern attrition rates or ITT analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-19 14:37:07 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Keene-1989">
<DESCRIPTION>
<P>Comment - All patients completed the study and no intention to treat analysis was needed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-19 14:37:51 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Larkin-1991">
<DESCRIPTION>
<P>Quote - "17 patients out of 22 completed the study"</P>
<P>Comment - The authors reported attrition but did not perform an intention to treat analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-19 14:38:12 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Larkin-1992">
<DESCRIPTION>
<P>Quote - "20 patients completed the study" This was out of total of 22 patients</P>
<P>Comment - Authors did not perform intention to treat analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-19 14:38:44 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Moglia-1986">
<DESCRIPTION>
<P>Comment - Attrition rate was repoted but no intention to treat analysis performed. 28 patients dropped out from the 90 patient sample, this constitutes a high risk of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-19 14:38:59 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Overweg-1984">
<DESCRIPTION>
<P>Comment - Study attrition was reported but no intention to treat analysis was performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-19 14:39:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pelliccia-1993">
<DESCRIPTION>
<P>Comment - Attrition was reported, but no intention to treat analysis preformed.Three out of 17 patients missing from analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-19 14:39:54 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pledger-1994">
<DESCRIPTION>
<P>Comment - No study attrition and no need for intention to treat analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-19 14:40:13 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Starreveld-1989">
<DESCRIPTION>
<P>Comment - Missing data was mentioned but no intention to treat analysis performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2013-02-19 14:40:14 +0000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 14:36:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alving-1989">
<DESCRIPTION>
<P>Comment - Outcomes were reported clearly</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-07 18:49:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Battaglia-1991">
<DESCRIPTION>
<P>Comment- Outcomes were reported clearly</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 14:36:45 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fr_x00f6_scher-1988">
<DESCRIPTION>
<P>Comment - Selective outcome reporting as the authors did not report seizure reduction or side effects of AED for first phase of the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 14:37:07 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Keene-1989">
<DESCRIPTION>
<P>Comment - Required primary outcomes not reported for first phase of study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 14:37:52 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Larkin-1991">
<DESCRIPTION>
<P>Comment - Primary and secondary outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 14:38:13 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Larkin-1992">
<DESCRIPTION>
<P>Comment - No selective reporting of outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-01 11:48:13 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Moglia-1986">
<DESCRIPTION>
<P>Comment - Authors did not report the required primary and secondary outcomes </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 14:39:00 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Overweg-1984">
<DESCRIPTION>
<P>Comment - Required primary and secondary outcomes were not reported for Phase 1 of the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 14:39:21 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pelliccia-1993">
<DESCRIPTION>
<P>Comment - no selective outcome reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 14:39:56 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pledger-1994">
<DESCRIPTION>
<P>Comment - no selective outcome reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 14:40:14 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Starreveld-1989">
<DESCRIPTION>
<P>Comment- Did not report primary and secondary outcomes for first phase of the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2013-02-19 14:39:57 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-01 11:20:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alving-1989">
<DESCRIPTION>
<P>None identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-01 09:10:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Battaglia-1991">
<DESCRIPTION>
<P>None identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 14:36:46 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fr_x00f6_scher-1988">
<DESCRIPTION>
<P>None identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-01 09:10:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Keene-1989">
<DESCRIPTION>
<P>None identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-01 10:32:03 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Larkin-1991">
<DESCRIPTION>
<P>None identified </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 14:38:14 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Larkin-1992">
<DESCRIPTION>
<P>None identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 14:38:45 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moglia-1986">
<DESCRIPTION>
<P>None identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 14:39:00 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Overweg-1984">
<DESCRIPTION>
<P>None identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 14:39:22 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pelliccia-1993">
<DESCRIPTION>
<P>None identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 14:39:57 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pledger-1994">
<DESCRIPTION>
<P>None identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-01 10:08:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Starreveld-1989">
<DESCRIPTION>
<P>None identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2013-02-19 14:40:50 +0000" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2013-02-19 14:40:46 +0000" MODIFIED_BY="Grade Profiler" NO="1" READONLY="YES">
<TITLE MODIFIED="2012-06-01 10:02:46 +0100" MODIFIED_BY="Grade Profiler">Flunarizine versus placebo for drug-resistant epilepsy</TITLE>
<TABLE COLS="7" ROWS="9">
<TR>
<TD COLSPAN="7">
<P>
<B>Flunarizine versus placebo for drug-resistant epilepsy</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with drug-resistant epilepsy<BR/>
<B>Settings:</B> Out-patient<BR/>
<B>Intervention:</B> Flunarizine versus placebo<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Flunarizine versus placebo</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>50% or greater reduction in seizure frequency</B>
<BR/>Number of seizures</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>13 per 100</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>20 per 100</B>
<BR/>(8 to 51)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.53 </B>
<BR/>(0.59 to 3.96)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>93<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>1 Study did not find a significant difference in seizure reduction</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Treatment withdrawal</B>
<BR/>Number of withdrawals</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>2 per 100</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>12 per 100</B>
<BR/>(3 to 49)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 7.11 </B>
<BR/>(1.73 to 29.30)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>247<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>1 study found a significant difference in treatment withdrawal. 3 did not find a significant difference in treatment withdrawal.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Adverse effects - Blurred vision</B>
<BR/>No of patients with blurred vision</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>6 per 100</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>26 per 100</B>
<BR/>(5 to 100)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 4.09 </B>
<BR/>(0.85 to 19.73)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>93<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>1 study did not find a significant difference in blurred vision.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Adverse effects - Dizziness</B>
<BR/>No of patients with dizziness</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>19 per 100</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>35 per 100</B>
<BR/>(14 to 88)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.82 </B>
<BR/>(0.72 to 4.61)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>93<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>1 study did not find a significant difference in dizziness.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Adverse effects - Fatigue</B>
<BR/>No of patients with fatigue</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>17 per 100</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>28 per 100</B>
<BR/>(10 to 79)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.66 </B>
<BR/>(0.59 to 4.64)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>93<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>1 study did not find a significant difference in fatigue</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Adverse effects - Irritability</B>
<BR/>No of patients with irritability</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>6 per 100</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>20 per 100</B>
<BR/>(4 to 100)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 3.07 </B>
<BR/>(0.6 to 15.68)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>93<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>1 study did not find a significant difference in Irritablity.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Adverse effects - Vomiting</B>
<BR/>No of patients with vomiting</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>4 per 100</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>17 per 100</B>
<BR/>(2 to 100)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 4.09 </B>
<BR/>(0.57 to 29.16)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>93<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>1 study did not find a significant difference in vomiting.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> 3 studies did not report outcomes adequately and intention-to-treat analysis not employed adequately</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2013-02-19 14:40:50 +0000" MODIFIED_BY="Grade Profiler" NO="2" READONLY="YES">
<TITLE MODIFIED="2012-06-01 10:03:32 +0100" MODIFIED_BY="Grade Profiler">Nimodipine versus placebo for drug-resistant epilepsy</TITLE>
<TABLE COLS="7" ROWS="4">
<TR>
<TD COLSPAN="7">
<P>
<B>Nimodipine versus placebo for drug-resistant epilepsy</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with drug-resistant epilepsy<BR/>
<B>Settings:</B> Out-patient<BR/>
<B>Intervention:</B> Nimodipine versus placebo<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Nimodipine versus placebo</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>50% or greater reduction in seizure frequency</B>
<BR/>Number of seizures</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 100</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 100</B>
<BR/>(0 to 0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 7.78 </B>
<BR/>(0.46 to 130.88)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>17<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>1 study did not find a significant difference in seizure reduction.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Treatment withdrawal</B>
<BR/>Number of withdrawals</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>11 per 100</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>25 per 100</B>
<BR/>(3 to 100)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 2.25 </B>
<BR/>(0.25 to 20.38)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>17<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>1 study did not find a significant difference in treatment withdrawal.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1 </SUP>This study had missing data and did not employ an intention-to-treat analysis, dropouts were excluded from the analysis</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2013-02-19 14:41:04 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2013-02-19 14:41:04 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2011-07-05 16:05:06 +0100" MODIFIED_BY="[Empty name]">50% responders and treatment withdrawal outcomes of cross-over trials</TITLE>
<TABLE COLS="3" ROWS="10">
<TR>
<TH>
<P>Trial</P>
</TH>
<TH>
<P>Participants (n)</P>
</TH>
<TH>
<P>50% responder (n)</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Alving-1989" TYPE="STUDY">Alving 1989</LINK> (FZN)</P>
</TD>
<TD VALIGN="TOP">
<P>Total randomised participants = 29, completing study = 22, having treatment withdrawn = 7, excluded from analysis = 7.</P>
</TD>
<TD VALIGN="TOP">
<P>4 participants had 50% SZ reduction on FZN. Overall no significant reduction in SZ frequency on FZN compared with PCB.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Battaglia-1991" TYPE="STUDY">Battaglia 1991</LINK> (FZN)</P>
</TD>
<TD>
<P>Total randomised participants = 20, completing study = 13, having treatment withdrawn = 7, excluded from analysis = 7.</P>
</TD>
<TD VALIGN="TOP">
<P>1 participant had 50% SZ reduction on FZN. Overall no significant reduction in SZ frequency on FZN compared with PCB.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Fr_x00f6_scher-1988" TYPE="STUDY">Fröscher 1988</LINK> (FZN)</P>
</TD>
<TD VALIGN="TOP">
<P>Total randomised participants = 30, completing study = 22, having treatment withdrawn = 8, excluded from analysis = 8.</P>
</TD>
<TD VALIGN="TOP">
<P>PCB-FZN sequence (n = 13): 2 patients had 50% SZ reduction on FZN. Overall significant reduction in SZ frequency on FZN compared with PCB. // FZN-PCB sequence (n = 9): 1 pt had 50% SZ reduction while 5 had SZ increase on FZN. Overall no significant SZ reduction on FZN compared with PCB.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Keene-1989" TYPE="STUDY">Keene 1989</LINK> (FZN)</P>
</TD>
<TD>
<P>Total randomised participants = 34, completing study = 34, having treatment withdrawn = 0, excluded from analysis = 0.</P>
</TD>
<TD VALIGN="TOP">
<P>5 participants had 50% SZ reduction on FZN. 8 participants had 50% SZ reduction on PCB compared with baseline.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Moglia-1986" TYPE="STUDY">Moglia 1986</LINK> (FZN)</P>
</TD>
<TD>
<P>Total randomised participants = 90, completing study = 90, having treatment withdrawn = 28, excluded from analysis = 28.</P>
</TD>
<TD VALIGN="TOP">
<P>14 participants had 50% SZ reduction on FZN. Overall significant SZ reduction on FZN compared with baseline.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Overweg-1984" TYPE="STUDY">Overweg 1984</LINK> (FZN)</P>
</TD>
<TD>
<P>Total randomised participants = 33, completing study = 30, having treatment withdrawn = 3, excluded from analysis = 3.</P>
</TD>
<TD VALIGN="TOP">
<P>7 participants had 50% SZ reduction while 9 participants had SZ increase on FZN. Overall significant SZ reduction on FZN compared with PCB.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Starreveld-1989" TYPE="STUDY">Starreveld 1989</LINK> (FZN)</P>
</TD>
<TD>
<P>Total randomised participants = 34, completing study = 25, having treatment withdrawn = 0, excluded from analysis = 9.</P>
</TD>
<TD VALIGN="TOP">
<P>5 participants had 50% SZ reduction on FZN. Overall no significant SZ reduction on FZN compared with PCB.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Larkin-1992" TYPE="STUDY">Larkin 1992</LINK> (NFD)</P>
</TD>
<TD>
<P>Total randomised participants = 22, completing study = 21, having treatment withdrawn = 1, excluded from analysis = 1.</P>
</TD>
<TD VALIGN="TOP">
<P>2 participants had 50% SZ reduction on NFD. 2 participants had 50% SZ reduction on PCB compared with baseline. No significant difference in SZ reduction between NFD and PCB.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Larkin-1991" TYPE="STUDY">Larkin 1991</LINK> (NMD)</P>
</TD>
<TD>
<P>Total randomised participants = 22, completing study = 17, having treatment withdrawn = 5, excluded from analysis = 5.</P>
</TD>
<TD VALIGN="TOP">
<P>7 participants had 50% reduction in partial SZ, 1 had 50% reduction in tonic-clonic SZ on NMD. 5 participants had 50% reduction in partial SZ, 1 had 50% reduction in tonic-clonic SZ on PCB compared with baseline. No significant difference in SZ reduction between NMD and PCB.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>FZN: flunarizine<BR/>NFD: nifedipine<BR/>NMD: nimodipine<BR/>PCB: placebo</P>
<P>SZ: seizure</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2012-05-03 16:36:05 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2011-07-05 16:05:19 +0100" MODIFIED_BY="[Empty name]">Numbers of participants experiencing adverse effects in cross-over trials</TITLE>
<TABLE COLS="10" ROWS="14">
<TR>
<TH VALIGN="TOP">
<P>Adverse effects</P>
</TH>
<TH VALIGN="TOP">
<P>
<LINK REF="STD-Alving-1989" TYPE="STUDY">Alving 1989</LINK>
<BR/>(n = 29)</P>
</TH>
<TH VALIGN="TOP">
<P>
<LINK REF="STD-Battaglia-1991" TYPE="STUDY">Battaglia 1991</LINK>
<BR/>(n = 20)</P>
</TH>
<TH VALIGN="TOP">
<P>
<LINK REF="STD-Fr_x00f6_scher-1988" TYPE="STUDY">Fröscher 1988</LINK>
<BR/>(n = 30)</P>
</TH>
<TH VALIGN="TOP">
<P>
<LINK REF="STD-Keene-1989" TYPE="STUDY">Keene 1989</LINK>
<BR/>(n = 34)</P>
</TH>
<TH VALIGN="TOP">
<P>
<LINK REF="STD-Moglia-1986" TYPE="STUDY">Moglia 1986</LINK>
<BR/>(n = 90)</P>
</TH>
<TH VALIGN="TOP">
<P>
<LINK REF="STD-Overweg-1984" TYPE="STUDY">Overweg 1984</LINK>
<BR/>(n = 23)</P>
</TH>
<TH VALIGN="TOP">
<P>
<LINK REF="STD-Starreveld-1989" TYPE="STUDY">Starreveld 1989</LINK>
<BR/>(n = 34)</P>
</TH>
<TH VALIGN="TOP">
<P>
<LINK REF="STD-Larkin-1992" TYPE="STUDY">Larkin 1992</LINK>
<BR/>(n = 22)</P>
</TH>
<TH VALIGN="TOP">
<P>
<LINK REF="STD-Larkin-1991" TYPE="STUDY">Larkin 1991</LINK>
<BR/>(n = 22)</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Change in mood</P>
</TD>
<TD VALIGN="TOP">
<P>FZN = 4 : PCB = 2</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>NFD = 0 : PCB = 1</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Change in appetite</P>
</TD>
<TD VALIGN="TOP">
<P>FZN = 7 : PCB = 6</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>FZN = PCB</P>
</TD>
<TD VALIGN="TOP">
<P>NFD = 0 : PCB = 1</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Drowsiness</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>FZN = 1 :<BR/>PCB = 0</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>FZN = 16 : PCB = 0</P>
</TD>
<TD VALIGN="TOP">
<P>FZN = 1 :<BR/>PCB = 0</P>
</TD>
<TD VALIGN="TOP">
<P>FZN = PCB</P>
</TD>
<TD VALIGN="TOP">
<P>NFD = 0 : PCB = 1</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Dry mouth</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>NFD = 1 : PCB = 1</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Fatigue</P>
</TD>
<TD VALIGN="TOP">
<P>FZN = 8 : PCB = 4</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Headache</P>
</TD>
<TD VALIGN="TOP">
<P>FZN = 4 : PCB = 5</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>FZN = PCB</P>
</TD>
<TD VALIGN="TOP">
<P>NFD = 2 : PCB = 0</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Irritability</P>
</TD>
<TD VALIGN="TOP">
<P>FZN = 9 : PCB = 5</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Poor memory</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>NFD = 1 : PCB = 0</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Tiredness</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>Approximately the same extent in both FZN and PCB</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Tremor</P>
</TD>
<TD VALIGN="TOP">
<P>FZN = 3 : PCB = 2</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Vertigo</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>FZN = PCB</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Weight change</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>FZN = PCB</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Other</P>
</TD>
<TD VALIGN="TOP">
<P>FZN = 8 : PCB = 8</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>No significant side effects were reported by any patients during the FZN phase compared with the PCB phase.</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>Neither NMD nor PCB significantly changed the severity of the following side effects compared with baseline period: agitation, double vision, flushing, headache, itching, nausea, palpitation, poor concentration, sedation, unsteadiness.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>FZN: flunarizine<BR/>NFD: nifedipine<BR/>NMD: nimodipine<BR/>PCB: placebo<BR/>
</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2012-12-12 11:31:51 +0000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2012-12-12 11:31:51 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Flunarizine versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.9614810591536096" CI_START="0.5929321329357837" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5326086956521738" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.597857583795425" LOG_CI_START="-0.22699501317577575" LOG_EFFECT_SIZE="0.1854312853098246" METHOD="MH" MODIFIED="2012-12-12 11:31:51 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.37819832216194316" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="EFFECT_SIZE" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="46" TOTAL_2="47" WEIGHT="100.00000000000001" Z="0.8812208196925074">
<NAME>50% or greater reduction in seizure frequency</NAME>
<GROUP_LABEL_1>Flunarizine (FZN)</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo (PCB)</GROUP_LABEL_2>
<GRAPH_LABEL_1>Placebo better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Flunarizine better</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.9614810591536096" CI_START="0.5929321329357837" DF="0" EFFECT_SIZE="1.5326086956521738" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.597857583795425" LOG_CI_START="-0.22699501317577575" LOG_EFFECT_SIZE="0.1854312853098246" NO="1" P_CHI2="1.0" P_Z="0.37819832216194316" STUDIES="1" TAU2="0.0" TOTAL_1="46" TOTAL_2="47" WEIGHT="100.00000000000001" Z="0.8812208196925074">
<NAME>Controlled plasma flunarizine concentration at 60 ng/ml</NAME>
<DICH_DATA CI_END="3.9614810591536105" CI_START="0.5929321329357837" EFFECT_SIZE="1.5326086956521738" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.597857583795425" LOG_CI_START="-0.22699501317577575" LOG_EFFECT_SIZE="0.1854312853098246" ORDER="53904" O_E="0.0" SE="0.4845224985470895" STUDY_ID="STD-Pledger-1994" TOTAL_1="46" TOTAL_2="47" VAR="0.23476205159831434" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.04001738125010626" CI_END="29.298653332378024" CI_START="1.7258334285567907" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="7.110878661087868" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="1.466847659133705" LOG_CI_START="0.23699887680817694" LOG_EFFECT_SIZE="0.8519232679709409" METHOD="MH" MODIFIED="2012-06-01 09:04:57 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8414466968163823" P_Q="0.8418218611825895" P_Z="0.006620446723290879" Q="0.03982569739819028" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="128" TOTAL_2="119" WEIGHT="100.0" Z="2.715356467902324">
<NAME>Treatment withdrawal</NAME>
<GROUP_LABEL_1>Flunarizine (FZN)</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo (PCB)</GROUP_LABEL_2>
<GRAPH_LABEL_1>More likely on PCB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>More likely on FNR</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="43.863087546291254" CI_START="0.8552891987005609" DF="0" EFFECT_SIZE="6.125" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="1.6420991986393225" LOG_CI_START="-0.06788701256618243" LOG_EFFECT_SIZE="0.7871060930365701" NO="1" P_CHI2="1.0" P_Z="0.07117777828720302" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="14" WEIGHT="51.88284518828452" Z="1.8043415604809343">
<NAME>15 mg per day</NAME>
<DICH_DATA CI_END="43.863087546291254" CI_START="0.8552891987005609" EFFECT_SIZE="6.125" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.6420991986393225" LOG_CI_START="-0.06788701256618243" LOG_EFFECT_SIZE="0.7871060930365701" ORDER="53905" O_E="0.0" SE="1.0044543650303739" STUDY_ID="STD-Fr_x00f6_scher-1988" TOTAL_1="16" TOTAL_2="14" VAR="1.0089285714285714" WEIGHT="51.88284518828452"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>Dose by body weight (BW): 5 mg/d for BW less than 20 kg, 10 mg/d for BW 20-40 kg, 15 mg/d for BW more than 40k</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="53906" O_E="0.0" SE="0.0" STUDY_ID="STD-Keene-1989" TOTAL_1="18" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.02.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="42" WEIGHT="0.0" Z="0.0">
<NAME>Dose by body weight (BW): 10 mg/d for BW less than 70 kg, 15 mg/d for BW more than 70 kg</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="53907" O_E="0.0" SE="0.0" STUDY_ID="STD-Moglia-1986" TOTAL_1="48" TOTAL_2="42" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="62.78224786407315" CI_START="1.0641997812342965" DF="0" EFFECT_SIZE="8.173913043478262" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" I2="0.0" ID="CMP-001.02.04" LOG_CI_END="1.7978368611806246" LOG_CI_START="0.027023165311549285" LOG_EFFECT_SIZE="0.912430013246087" NO="4" P_CHI2="1.0" P_Z="0.043405870223513825" STUDIES="1" TAU2="0.0" TOTAL_1="46" TOTAL_2="47" WEIGHT="48.11715481171549" Z="2.0197832991099194">
<NAME>Controlled plasma flunarizine concentration at 60 ng/ml</NAME>
<DICH_DATA CI_END="62.78224786407315" CI_START="1.0641997812342965" EFFECT_SIZE="8.173913043478262" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.7978368611806246" LOG_CI_START="0.027023165311549285" LOG_EFFECT_SIZE="0.912430013246087" ORDER="53908" O_E="0.0" SE="1.0401847306226604" STUDY_ID="STD-Pledger-1994" TOTAL_1="46" TOTAL_2="47" VAR="1.0819842738205365" WEIGHT="48.11715481171549"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.2370368648607593" CI_END="3.6977169621466937" CI_START="1.429260604739822" CI_STUDY="99" CI_TOTAL="99" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="2.298913043478261" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="36" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.5679336654812939" LOG_CI_START="0.15511142324971794" LOG_EFFECT_SIZE="0.36152254436550596" METHOD="MH" MODIFIED="2012-05-23 10:17:29 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8622429796201342" P_Q="0.8681668432710861" P_Z="6.437579691996148E-6" Q="3.176927277144582" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="368" TOTAL_2="376" WEIGHT="800.0" Z="4.511483483236604">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Flunarizine (FZN)</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo (PCB)</GROUP_LABEL_2>
<GRAPH_LABEL_1>more likely on PCB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>more likely on FNR</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="12.989121529977739" CI_START="0.4375763515677476" DF="0" EFFECT_SIZE="2.3840579710144927" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="1.1135797802043563" LOG_CI_START="-0.35894615710688077" LOG_EFFECT_SIZE="0.37731681154873775" NO="1" P_CHI2="1.0" P_Z="0.18681842997604486" STUDIES="1" TAU2="0.0" TOTAL_1="46" TOTAL_2="47" WEIGHT="100.00000000000001" Z="1.32004968507859">
<NAME>Altered concentration</NAME>
<DICH_DATA CI_END="12.989121529977739" CI_START="0.4375763515677476" EFFECT_SIZE="2.3840579710144927" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="1.1135797802043563" LOG_CI_START="-0.35894615710688077" LOG_EFFECT_SIZE="0.37731681154873775" ORDER="53909" O_E="0.0" SE="0.6581601249019974" STUDY_ID="STD-Pledger-1994" TOTAL_1="46" TOTAL_2="47" VAR="0.43317475001101274" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="19.733695224855953" CI_START="0.8464311128889416" DF="0" EFFECT_SIZE="4.086956521739131" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="3" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="1.2952084164990436" LOG_CI_START="-0.07240838133483199" LOG_EFFECT_SIZE="0.6114000175821058" NO="2" P_CHI2="1.0" P_Z="0.021274619267055747" STUDIES="1" TAU2="0.0" TOTAL_1="46" TOTAL_2="47" WEIGHT="100.00000000000001" Z="2.3030750777157385">
<NAME>Blurred vision</NAME>
<DICH_DATA CI_END="19.733695224855953" CI_START="0.8464311128889416" EFFECT_SIZE="4.086956521739131" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="3" LOG_CI_END="1.2952084164990436" LOG_CI_START="-0.07240838133483199" LOG_EFFECT_SIZE="0.6114000175821058" ORDER="53910" O_E="0.0" SE="0.6112699407685636" STUDY_ID="STD-Pledger-1994" TOTAL_1="46" TOTAL_2="47" VAR="0.3736509404872032" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.835084355387341E-32" CI_END="6.41944485645014" CI_START="0.4163154661276463" DF="0" EFFECT_SIZE="1.634782608695652" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" I2="100.0" ID="CMP-001.03.03" LOG_CI_END="0.8074974725852301" LOG_CI_START="-0.3805774547650938" LOG_EFFECT_SIZE="0.21346000891006814" NO="3" P_CHI2="0.0" P_Z="0.35465786897821594" STUDIES="1" TAU2="0.0" TOTAL_1="46" TOTAL_2="47" WEIGHT="99.99999999999999" Z="0.9255923737278473">
<NAME>Diplopia</NAME>
<DICH_DATA CI_END="6.419444856450142" CI_START="0.4163154661276463" EFFECT_SIZE="1.6347826086956523" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.8074974725852302" LOG_CI_START="-0.3805774547650938" LOG_EFFECT_SIZE="0.2134600089100682" ORDER="53911" O_E="0.0" SE="0.5310219146330372" STUDY_ID="STD-Pledger-1994" TOTAL_1="46" TOTAL_2="47" VAR="0.2819842738205366" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.607673740620214" CI_START="0.7160663721235829" DF="0" EFFECT_SIZE="1.816425120772947" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="9" I2="0.0" ID="CMP-001.03.04" LOG_CI_END="0.6634817200538999" LOG_CI_START="-0.1450467211124132" LOG_EFFECT_SIZE="0.2592174994707433" NO="4" P_CHI2="1.0" P_Z="0.09860741886654849" STUDIES="1" TAU2="0.0" TOTAL_1="46" TOTAL_2="47" WEIGHT="100.0" Z="1.6516426562960387">
<NAME>Dizziness</NAME>
<DICH_DATA CI_END="4.607673740620214" CI_START="0.7160663721235829" EFFECT_SIZE="1.816425120772947" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="9" LOG_CI_END="0.6634817200538999" LOG_CI_START="-0.1450467211124132" LOG_EFFECT_SIZE="0.2592174994707433" ORDER="53912" O_E="0.0" SE="0.3613798347053245" STUDY_ID="STD-Pledger-1994" TOTAL_1="46" TOTAL_2="47" VAR="0.13059538493164766" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.63585949683195" CI_START="0.5946432839287331" DF="0" EFFECT_SIZE="1.6603260869565217" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="8" I2="0.0" ID="CMP-001.03.05" LOG_CI_END="0.666130264937103" LOG_CI_START="-0.22574348179902995" LOG_EFFECT_SIZE="0.22019339156903658" NO="5" P_CHI2="1.0" P_Z="0.2034138718487395" STUDIES="1" TAU2="0.0" TOTAL_1="46" TOTAL_2="47" WEIGHT="100.0" Z="1.271885381819959">
<NAME>Fatigue</NAME>
<DICH_DATA CI_END="4.63585949683195" CI_START="0.5946432839287331" EFFECT_SIZE="1.6603260869565217" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="8" LOG_CI_END="0.666130264937103" LOG_CI_START="-0.22574348179902995" LOG_EFFECT_SIZE="0.22019339156903658" ORDER="53913" O_E="0.0" SE="0.398631848631809" STUDY_ID="STD-Pledger-1994" TOTAL_1="46" TOTAL_2="47" VAR="0.15890735074361348" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="15.675873252477773" CI_START="0.5993642270914343" DF="0" EFFECT_SIZE="3.0652173913043477" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" I2="0.0" ID="CMP-001.03.06" LOG_CI_END="1.1952317433253279" LOG_CI_START="-0.22230918137771638" LOG_EFFECT_SIZE="0.4864612809738058" NO="6" P_CHI2="1.0" P_Z="0.07707622572326185" STUDIES="1" TAU2="0.0" TOTAL_1="46" TOTAL_2="47" WEIGHT="100.00000000000001" Z="1.7679083555725343">
<NAME>Irritability</NAME>
<DICH_DATA CI_END="15.67587325247778" CI_START="0.5993642270914341" EFFECT_SIZE="3.0652173913043477" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="1.195231743325328" LOG_CI_START="-0.22230918137771652" LOG_EFFECT_SIZE="0.4864612809738058" ORDER="53914" O_E="0.0" SE="0.6335840262072435" STUDY_ID="STD-Pledger-1994" TOTAL_1="46" TOTAL_2="47" VAR="0.401428718264981" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="29.161416696724327" CI_START="0.5727847101633532" DF="0" EFFECT_SIZE="4.086956521739131" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" I2="0.0" ID="CMP-001.03.07" LOG_CI_END="1.4648086187071352" LOG_CI_START="-0.24200858354292368" LOG_EFFECT_SIZE="0.6114000175821058" NO="7" P_CHI2="1.0" P_Z="0.0649824648583024" STUDIES="1" TAU2="0.0" TOTAL_1="46" TOTAL_2="47" WEIGHT="100.0" Z="1.8453787311285543">
<NAME>Vomiting</NAME>
<DICH_DATA CI_END="29.161416696724327" CI_START="0.5727847101633533" EFFECT_SIZE="4.086956521739131" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="1.4648086187071352" LOG_CI_START="-0.2420085835429236" LOG_EFFECT_SIZE="0.6114000175821058" ORDER="53915" O_E="0.0" SE="0.7628789378535342" STUDY_ID="STD-Pledger-1994" TOTAL_1="46" TOTAL_2="47" VAR="0.5819842738205365" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="14.329670666124995" CI_START="0.5180614870056378" DF="0" EFFECT_SIZE="2.7246376811594204" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" I2="0.0" ID="CMP-001.03.08" LOG_CI_END="1.1562362092718605" LOG_CI_START="-0.2856186922190113" LOG_EFFECT_SIZE="0.43530875852642453" NO="8" P_CHI2="1.0" P_Z="0.11986717759148986" STUDIES="1" TAU2="0.0" TOTAL_1="46" TOTAL_2="47" WEIGHT="100.00000000000001" Z="1.555331337632458">
<NAME>Insomnia</NAME>
<DICH_DATA CI_END="14.329670666124995" CI_START="0.5180614870056378" EFFECT_SIZE="2.7246376811594204" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="1.1562362092718605" LOG_CI_START="-0.2856186922190113" LOG_EFFECT_SIZE="0.43530875852642453" ORDER="53916" O_E="0.0" SE="0.644451400148894" STUDY_ID="STD-Pledger-1994" TOTAL_1="46" TOTAL_2="47" VAR="0.4153176071538699" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2012-05-23 13:14:41 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Nimodipine versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="130.8826896836731" CI_START="0.46219883856833766" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="7.777777777777778" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="2.1168822113178853" LOG_CI_START="-0.3351711501680211" LOG_EFFECT_SIZE="0.8908555305749319" METHOD="MH" MODIFIED="2012-05-23 13:14:18 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.1544033247403703" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="8" TOTAL_2="9" WEIGHT="100.0" Z="1.424149068515468">
<NAME>50% or greater reduction in seizure frequency</NAME>
<GROUP_LABEL_1>Placebo better</GROUP_LABEL_1>
<GROUP_LABEL_2>Plaqcebo (PCB)</GROUP_LABEL_2>
<GRAPH_LABEL_1>Placebo better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Nimodipine better</GRAPH_LABEL_2>
<DICH_DATA CI_END="130.8826896836731" CI_START="0.4621988385683378" EFFECT_SIZE="7.777777777777778" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1168822113178853" LOG_CI_START="-0.33517115016802096" LOG_EFFECT_SIZE="0.8908555305749319" ORDER="53917" O_E="0.0" SE="1.4403482823967175" STUDY_ID="STD-Pelliccia-1993" TOTAL_1="8" TOTAL_2="9" VAR="2.0746031746031743" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="20.376389679930686" CI_START="0.24844931214611624" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.25" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="1.309127237522174" LOG_CI_START="-0.604762201299449" LOG_EFFECT_SIZE="0.3521825181113625" METHOD="MH" MODIFIED="2012-05-23 13:14:41 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.4707115758726579" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="8" TOTAL_2="9" WEIGHT="100.0" Z="0.7213217623562314">
<NAME>Treatment withdrawal</NAME>
<GROUP_LABEL_1>More likely on PCB</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo (PCB)</GROUP_LABEL_2>
<GRAPH_LABEL_1>More likely on PCB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>More likely on NMD</GRAPH_LABEL_2>
<DICH_DATA CI_END="20.376389679930686" CI_START="0.24844931214611624" EFFECT_SIZE="2.25" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.309127237522174" LOG_CI_START="-0.604762201299449" LOG_EFFECT_SIZE="0.3521825181113625" ORDER="53918" O_E="0.0" SE="1.1242281302693367" STUDY_ID="STD-Pelliccia-1993" TOTAL_1="8" TOTAL_2="9" VAR="1.2638888888888888" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2013-02-19 15:39:16 +0000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2013-02-19 14:59:58 +0000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAcoAAANDCAYAAAAtvF/lAABqI0lEQVR42uy9D2RW7x///yFJJonk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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2013-02-19 15:39:16 +0000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAEZCAMAAABxStv9AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2013-02-19 15:34:41 +0000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2009-10-07 16:46:48 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2009-10-07 16:44:30 +0100" MODIFIED_BY="[Empty name]">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-10-07 16:46:48 +0100" MODIFIED_BY="[Empty name]">
<P>#1        (epilep*) or (seizure*) or (convuls*)</P>
<P>#2        MeSH descriptor Epilepsy explode all trees</P>
<P>#3        MeSH descriptor Seizures explode all trees</P>
<P>#4        (#1 OR #2 OR #3)</P>
<P>#5        MeSH descriptor Calcium Channel Blockers explode all trees</P>
<P>#6        calcium NEXT channel NEXT blocker*</P>
<P>#7        (calcium NEXT antagonist*)</P>
<P>#8        (amlodipine) or (amrinone) or (bencyclane) or (bepridil) or (cinnarizine)</P>
<P>#9        (conotoxins) or (diltiazem) or (felodipine) or (fendiline) or (flunarazine)</P>
<P>#10      (gallopamil) or (isradipine) or (lidoflazine) or (mibefradil) or (nicardipine)</P>
<P>#11      (nifedipine) or (nimodipine) or (nisoldipine) or (nitrendipine) or (perhexiline)</P>
<P>#12      (prenylamine) or (verapamil)</P>
<P>#13      (#5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12)</P>
<P>#14      (#4 AND #13)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2013-02-19 15:34:41 +0000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2009-10-07 16:46:58 +0100" MODIFIED_BY="[Empty name]">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-02-19 15:34:41 +0000" MODIFIED_BY="[Empty name]">
<P>For the most recent update of this review (January 2013) we used the following search strategy which is based on the Cochrane Highly Sensitive Search Strategy for identifying randomised trials published in Lefebvre 2011.</P>
<P>1. exp Calcium Channel Blockers/</P>
<P>2. ((calcium adj channel adj blocker$) or (calcium adj antagonist$) or amlodipine or amrinone or bencyclane or bepridil or cinnarizine or conotoxins or diltiazem or felodipine or fendiline or flunarizine or gallopamil or isradipine or lidoflazine or mibefradil or nicardipine or nifedipine or nimodipine or nisoldipine or nitrendipine or perhexiline or prenylamine or verapamil).tw.</P>
<P>3. 1 or 2</P>
<P>4. (randomised controlled trial or controlled clinical trial).pt. or (randomised or placebo or randomly).ab.</P>
<P>5. clinical trials as topic.sh.</P>
<P>6. trial.ti.</P>
<P>7. 4 or 5 or 6</P>
<P>8. exp animals/ not humans.sh.</P>
<P>9. 7 not 8</P>
<P>10. exp Epilepsy/</P>
<P>11. exp Seizures/</P>
<P>12. (epilep$ or seizure$ or convuls$).tw.</P>
<P>13. 10 or 11 or 12</P>
<P>14. 9 and 13</P>
<P>15. 3 and 14</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2012-05-30 12:53:48 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2012-05-30 12:53:45 +0100" MODIFIED_BY="[Empty name]">SCOPUS search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-05-30 12:53:48 +0100" MODIFIED_BY="[Empty name]">
<P>(((TITLE-ABS-KEY(epilep* OR "infantile spasm")) OR ((TITLE-ABS-KEY(seizure* OR convuls*) AND NOT TITLE-ABS-KEY(*eclampsia)) AND SUBJAREA(mult OR agri OR bioc OR immu OR neur OR phar OR mult OR medi OR nurs OR vete OR dent OR heal))</P>
<P>OR ((TITLE-ABS-KEY(syndrome) AND TITLE-ABS-KEY(aicardi OR angelman OR doose OR dravet OR "landau kleffner" OR "lennox gastaut" OR ohtahara OR panayiotopoulos OR rasmussen OR rett OR "sturge weber" OR "unverricht lundborg" OR west)) AND SUBJAREA(mult OR agri OR bioc OR immu OR neur OR phar OR mult OR medi OR nurs OR vete OR dent OR heal))</P>
<P>OR (TITLE-ABS-KEY("ring chromosome 20" OR "R20" OR "myoclonic encephalopathy" OR "pyridoxine dependency") AND SUBJAREA(mult OR agri OR bioc OR immu OR neur OR phar OR mult OR medi OR nurs OR vete OR dent OR heal)))</P>
<P>AND</P>
<P>(((TITLE-ABS-KEY(trial AND random*) AND NOT KEY(nonhuman) AND NOT KEY(animals)) AND SUBJAREA(mult OR agri OR bioc OR immu OR neur OR phar OR mult OR medi OR nurs OR vete OR dent OR heal))</P>
<P>OR (TITLE-ABS-KEY((controlled OR placebo OR cluster OR "head to head" OR factorial OR crossover OR "cross over" OR "double blind*" OR "single blind*" OR "multi arm") PRE/2 (trial OR method OR procedure)) AND NOT KEY(nonhuman) AND NOT KEY(animals) AND SUBJAREA(mult OR agri OR bioc OR immu OR neur OR phar OR mult OR medi OR nurs OR vete OR dent OR heal))))</P>
<P>AND</P>
<P>((TITLE-ABS-KEY("calcium channel block*" OR "calcium antagonis*") AND SUBJAREA(mult OR agri OR bioc OR immu OR neur OR phar OR mult OR medi OR nurs OR vete OR dent OR heal))</P>
<P>OR ((TITLE-ABS-KEY(amlodipine OR amrinone OR bencyclane OR bepridil OR cinnarizine OR conotoxins OR diltiazem OR felodipine OR fendiline OR flunarizine OR gallopamil OR isradipine OR lidoflazine OR mibefradil OR nicardipine OR nifedipine OR nimodipine OR nisoldipine)</P>
<P>OR TITLE-ABS-KEY(nitrendipine OR perhexiline OR prenylamine OR verapamil)) AND SUBJAREA(mult OR agri OR bioc OR immu OR neur OR phar OR mult OR medi OR nurs OR vete OR dent OR heal)))</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;0 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;11 studies included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;19 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;302 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;302 of records after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;422 of records identified through database searching&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;0 additional records identified through other sources&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;283 records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;7 full-text articles excluded (from 8 reports), with reasons&lt;/p&gt;&lt;p&gt;Not randomised trials (n=3)&lt;/p&gt;&lt;p&gt;shorter than 8 weeks (n=1)&lt;/p&gt;&lt;p&gt;Tapered off original AEDs and used alternatives (n=1)&lt;/p&gt;&lt;p&gt;Did not measure primary outcome of review (n=2)&lt;/p&gt;" WIDTH="177"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>